751 N2755 v.1 1979

The Lipid Research Clinics
Population Studies Data Book

Volume I
The Prevalence
Study



# The Lipid Research Clinics Population Studies Data Book

# Volume I The Prevalence Study

Aggregate Distributions of Lipids, Lipoproteins and selected variables in 11 North American Populations

Lipid Metabolism Branch Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service
National Institutes of Health

N2755 V.1 1979

•

# **Table of Contents**

	Table of Contents	a <b>ge</b> 3
v	List of Tables and Figures	4
	Preface	10
	Overview of Lipid Research Clinics Program	11
	Population Studies	
	LRC Program Structure	
	The Prevalence Study	14
	Visit 1 and Visit 2 Screens: Objectives and Descriptions	
	Visit 1. Visit 2.	
	Methods	17
	Lipids and Lipoproteins Education Occupation Smoking Blood Pressure Height Weight Skinfold Body Mass (Quetelet) Index Sex Hormone Usage	
	Data Presentation	18
	Introduction Exclusions Format of Data Book Definitions	
	Tables and Figures	20
-	References	128
	Key Personnel—LRC Prevalence Study Staff	129

# **List of Tables and Figures**

Pa	age
Introductory Figures	•
<ol> <li>Organizational Flow Chart of the Program</li> <li>North American Lipid Research Clinics and Central Support Agencies</li> <li>Visit-1 and Visit-2 Response Rates</li> </ol>	
Introductory Tables	15
Target and Study Populations (North America)	
■ Age, Race, Sex Distributions and Sex Hormone Usage. Visit 1; Visit 2, Random Sample	22
Tables Tables	
<ol> <li>Age, Race, Sex Distributions—Visit 1</li> <li>Age, Race, Sex Distributions—Visit 2</li> <li>Sex Hormone Usage, Females, by Age and Race—Visit 1</li> <li>Sex Hormone Usage, White Females, by Age—Visit 2, Random Sample</li> </ol>	
Plasma Lipids and Lipoproteins Visit 1	27
Plasma Total Cholesterol	28
Tables: Means and Selected Percentiles	
<ol> <li>6. White Males</li> <li>7. White Females (Total)</li> <li>8. White Females (Sex Hormone Users)</li> <li>9. White Females (Non-Sex Hormone Users)</li> <li>10. Black Males</li> <li>11. Black Females (Total)</li> <li>12. Black Females (by Sex Hormone Usage)</li> </ol>	
Figures	
<ol> <li>Means and Selected Percentiles—White Males</li> <li>Means and Selected Percentiles—White Females (Total)</li> <li>Comparison of Medians by Sex Hormone Usage—White Females</li> <li>Comparison of Medians—White Males/White Females (Total)</li> <li>Means and Selected Percentiles—Black Males</li> <li>Means and Selected Percentiles—Black Females (Total)</li> <li>Comparison of Medians by Sex Hormone Usage—Black Females</li> <li>Comparison of Medians—Black Males/Black Females (Total)</li> <li>Cumulative Frequencies:</li> <li>Whites, 0-19 Years</li> <li>Whites, 20-39 Years</li> <li>Whites, 40-59 Years</li> <li>Blacks, 0-19 Years</li> <li>Blacks, 20-39 Years</li> <li>Blacks, 40-59 Years</li> <li>Blacks, 40-59 Years</li> </ol>	
Plasma Triglyceride	39
Tables: Means and Selected Percentiles	
13. White Males 14. White Females (Total) 15. White Females (Sex Hormone Users) 16. White Females (Non-Sex Hormone Users) 17. Black Males 18. Black Females (Total) 19. Black Females (by Sex Hormone Usage)	

igur	res	
20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32.	Means and Selected Percentiles—White Males Means and Selected Percentiles—White Females (Total) Comparison of Medians by Sex Hormone Usage—White Females Comparison of Medians—White Males/White Females (Total) Means and Selected Percentiles—Black Males Means and Selected Percentiles—Black Females (Total) Comparison of Medians by Sex Hormone Usage—Black Females Comparison of Medians—Black Males/Black Females (Total) Cumulative Frequencies: Whites, 0-19 Years Whites, 20-39 Years Whites, 40-59 Years Blacks, 0-19 Years Blacks, 20-39 Years Blacks, 40-59 Years Blacks, 40-59 Years	
■ P V	lasma Lipids and Lipoproteins isit 2—Random Sample	51
Plas	ma Total Cholesterol	52
able	s: Means and Selected Percentiles	
21. 22.	White Males White Females (Total) White Females (Sex Hormone Users) White Females (Non-Sex Hormone Users)	
igur	es	
35. 36. 37. 38. 39. 40.	Means and Selected Percentiles—White Males Means and Selected Percentiles—White Females (Total) Comparison of Medians by Sex Hormone Usage—White Females Comparison of Medians—White Males/White Females (Total) Cumulative Frequencies: Whites, 0-19 Years Whites, 20-39 Years Whites, 40-59 Years Whites, 60+ Years	
Plas	ma Triglyceride	58
able	s: Means and Selected Percentiles	
25. 26.	White Males White Females (Total) White Females (Sex Hormone Users) White Females (Non-Sex Hormone Users)	
igur	es	
43. 44. 45. 46. 47.	Means and Selected Percentiles—White Males Means and Selected Percentiles—White Females (Total) Comparison of Medians by Sex Hormone Usage—White Females Comparison of Medians—White Males/White Females (Total) Cumulative Frequencies: Whites, 0-19 Years Whites, 20-39 Years	
	Whites, 40-59 Years Whites, 60+ Years	

# List of Tables and Figures (Cont'd)

Plasma VLDL-Cholesterol	Page 64
Tables: Means and Selected Percentiles	
28. White Males 29. White Females (Total) 30. White Females (Sex Hormone Users) 31. White Females (Non-Sex Hormone Users)	
Figures	
<ul> <li>50. Means and Selected Percentiles—White Males</li> <li>51. Means and Selected Percentiles—White Females (Total)</li> <li>52. Comparison of Medians by Sex Hormone Usage—White Females</li> <li>53. Comparison of Medians—White Males/White Females (Total) Cumulative Frequencies:</li> <li>54. Whites, 0-19 Years</li> <li>55. Whites, 20-39 Years</li> <li>56. Whites, 40-59 Years</li> <li>57. Whites, 60+ Years</li> </ul>	
Plasma LDL-Cholesterol	70
Tables: Means and Selected Percentiles	
<ul><li>32. White Males</li><li>33. White Females (Total)</li><li>34. White Females (Sex Hormone Users)</li><li>35. White Females (Non-Sex Hormone Users)</li></ul>	
Figures	
<ul> <li>58. Means and Selected Percentiles—White Males</li> <li>59. Means and Selected Percentiles—White Females (Total)</li> <li>60. Comparison of Medians by Sex Hormone Usage—White Females</li> <li>61. Comparison of Medians—White Males/White Females (Total) Cumulative Frequencies:</li> <li>62. Whites, 0-19 Years</li> <li>63. Whites, 20-39 Years</li> <li>64. Whites 40-59 Years</li> <li>65. Whites, 60+ Years</li> </ul>	
Plasma HDL-Cholesterol	76
Tables: Means and Selected Percentiles	
<ul><li>36. White Males</li><li>37. White Females (Total)</li><li>38. White Females (Sex Hormone Users)</li><li>39. White Females (Non-Sex Hormone Users)</li></ul>	
Figures	
<ul> <li>66. Means and Selected Percentiles—White Males</li> <li>67. Means and Selected Percentiles—White Females (Total)</li> <li>68. Comparison of Medians by Sex Hormone Usage—White Females</li> <li>69. Comparison of Medians—White Males/White Females (Total) Cumulative Frequencies:</li> <li>70. Whites, 0-19 Years</li> <li>71. Whites, 20-39 Years</li> <li>72. Whites, 40-59 Years</li> </ul>	
73. Whites, 60 + Years	

Blood Pressure—Visit 2, Random Sample Standard Sphygmomanometer	33
Systolic Blood Pressure Measurements	34
Tables: Means and Selected Percentiles	
40. White Males 41. White Females	
Figures	
<ul> <li>74. Means and Selected Percentiles—White Males</li> <li>75. Means and Selected Percentiles—White Females (Total)</li> <li>76. Comparison of Medians—White Males/White Females (Total)</li> </ul>	
Diastolic Blood Pressure Measurements	7
Tables: Means and Selected Percentiles	
42. White Males 43. White Females (Total)	
Figures	
<ul> <li>77. Means and Selected Percentiles—White Males</li> <li>78. Means and Selected Percentiles—White Females (Total)</li> <li>79. Comparison of Medians—White Males/White Females (Total)</li> </ul>	
■ Blood Pressure—Visit 2, Random Sample	04
	91
Systolic Blood Pressure Measurements	92
Tables: Means and Selected Percentiles	
44. White Males 45. White Females (Total)	
Figures	
<ul> <li>80. Means and Selected Percentiles—White Males</li> <li>81. Means and Selected Percentiles—White Females (Total)</li> <li>82. Comparison of Medians—White Males/White Females (Total)</li> </ul>	
Diastolic Blood Pressure Measurements 9	5
Tables: Means and Selected Percentiles	
46. White Males 47. White Females (Total)	
Figures	
<ul> <li>83. Means and Selected Percentiles—White Males</li> <li>84. Means and Selected Percentiles—White Females (Total)</li> <li>85. Comparison of Medians—White Males/White Females (Total)</li> </ul>	

# List of Tables and Figures (Contd.)

Page
■ Comparison of Standard and Random-Zero Sphygmomanometer Measurements
Figures
86. Comparison of Medians—White Males 87. Comparison of Medians—White Females (Total)
■ Anthropometric Measurements Height—Visit 2, Random Sample
Tables: Means and Selected Percentiles
48. White Males 49. White Females (Total)
Figures Figures
<ul><li>88. Means and Selected Percentiles—White Males</li><li>89. Means and Selected Percentiles—White Females (Total)</li><li>90. Comparison of Medians—White Males/White Females (Total)</li></ul>
Weight—Visit 2, Random Sample 105
Tables: Means and Selected Percentiles
50. White Males 51. White Females (Total)
Figures
<ul><li>91. Means and Selected Percentiles—White Males</li><li>92. Means and Selected Percentiles—White Females (Total)</li><li>93. Comparison of Medians—White Males/White Females (Total)</li></ul>
Triceps Skinfold—Visit 2, Random Sample
Tables: Means and Selected Percentiles
52. White Males 53. White Females (Total)
Figures
<ul><li>94. Means and Selected Percentiles—White Males</li><li>95. Means and Selected Percentiles—White Females (Total)</li><li>96. Comparison of Medians—White Males/White Females (Total)</li></ul>

Quetelet Index—Visit 2, Random Sample
Tables: Means and Selected Percentiles
54. White Males 55. White Females (Total)
Figures
97. Means and Selected Percentiles—White Males 98. Means and Selected Percentiles—White Females (Total) 99. Comparison of Medians—White Males/White Females (Total)
■ Cigarette Smoking Status—Visit 2, Random Sample 117
Table
56. Cigarette Smoking Status—Whites, by Age and Sex
Figures
<ul> <li>100. Cigarette Smoking Status—White Males</li> <li>101. Cigarette Smoking Status—White Females (Total)</li> <li>102. Smokers by Age and Sex—White Males</li> <li>103. Smokers by Age and Sex—White Females (Total)</li> </ul>
■ Education and Occupation of Head of Household— Visits 1 and 2 12
Tables
Education:
57. Whites—Visit 1 58. Blacks—Visit 1 59. Whites—Visit 2
Occupation:
60. Whites—Visit 1 61. Blacks—Visit 1 62. Whites—Visit 2

### **Preface**

The Lipid Research Clinics (LRC) Population Studies—a major component of the National Heart, Lung, and Blood Institute—consist of the Prevalence Study, the Family Study, and the Mortality Follow-up Study. In the aggregate, they are to provide improved information on the prevalence of hyperlipidemia and hyperlipoproteinemia, and on their determinants and sequelae. The three studies are closely related, especially since they draw on the same population base.

That base consists of 14 separate well-defined populations, 10 in the United States, one in Canada, two in the USSR and one in Israel. Each population study was conducted according to an identical protocol with stringent standardization of methodology. Each study has the potential to be analyzed independently as well as to contribute to a common data pool. Special features of the aggregate population study are large numbers of participants of both sexes; socio-economic, geographic and ethnic diversity; and a wide age range.

A huge volume of data has already been assembled from the Prevalence Study and is in the process of being collected in the Family and Follow-up Studies. The LRC Program faces the challenge of analyzing this data set effectively and sharing the findings with the community as promptly as possible. To facilitate this process it is producing a series of Data Books, of which this is the first. They are timed to appear shortly after the various data files have undergone appropriate editing. The Data Books will consist of tabulations and displays of the distribution of various key measurements made in the LRC Population Studies, together with some simple descriptive statistics on an age-, race-, sex-specific basis. More complex correlations and analysis will appear in other formats.

The final verification of the North American Prevalence Study data was completed in mid-1978. We are pleased to be able to provide the medical community with these selected findings so soon after the actual closure of the data set.

I would like to take this opportunity to thank the many individuals involved in the Prevalence Study who are responsible for its success. Special acknowledgements are extended to the Lipid Metabolism Advisory Committee and to the Epidemiology Analysis Executive Committee which provided invaluable advice in study design, implementation and evaluation of the Prevalence Study. The membership of these two groups, as well as key personnel involved in Prevalence Study data collection, are listed at the end of the Data Book.

Bethesda, Maryland July, 1979

> Basil M. Rifkind, M.D., F.R.C.P. Chief, Lipid Metabolism Branch Project Officer, Lipid Research Clinics Program Division of Heart and Vascular Diseases National Heart, Lung, and Blood Institute

### **Overview of The Lipid Research Clinics Program**

The Lipid Research Clinics (LRC) Program was created in 1971 under the aegis of the Lipid Metabolism Branch, National Heart, Lung, and Blood Institute, National Institutes of Health.

A network of 12 LRC's and five central support agencies was established with the following metabolism.


A network of 12 LRC's and five central support agencies was established with the following major objectives:

- to evaluate current techniques for diagnosis of hyperlipoproteinemia;
- to acquire data across all age groups on the prevalence of different types of hyperlipoproteinemia, particularly genetically determined forms;
- to collect high-quality data on the prevalence and incidence of atherosclerosis in different patterns of hyperlipoproteinemia; and
- to improve methods for detection, diagnosis and medical care of coronary heart disease.

Two major sets of collaborative studies were undertaken to meet these objectives. The first, the *Population Studies*, is a series of epidemiologic surveys of the distribution, causes and consequences of dyslipoproteinemias (1). The second, the *Coronary Primary Prevention Trial*, is a double-blind clinical trial testing the hypothesis that long-term reduction of serum cholesterol in hypercholesterolemic men, initially free of coronary heart disease (CHD), will lower the incidence of CHD.

Figure 1 presents the organizational chart for the LRC Program.

Figure 1
Organizational Flow Chart
of the Lipid Research Clinics Program



### Overview (cont'd.)

### **Population Studies**

The Population Studies encompass three major studies sharing the same general population base.

The Prevalence Study, initiated in 1972 to determine the prevalence of different types of dyslipo-proteinemias, consists of a series of two screening visits. Each of the 10 participating North American LRC's evaluated subjects selected from well-defined populations; data collection and editing were completed in 1978. As a result of the establishment of the US-USSR Joint Program in Cardiovascular Disease, clinics were set up in Moscow and Leningrad, which closely followed the collaborative Prevalence Study protocol (2).

A final addition to this collaborative effort occurred in 1975 with the establishment of an LRC in Jerusalem, Israel.

The Family Study, started in 1975, provides data on the relationship of familial and genetic attributes to plasma lipids and lipoproteins. A sample of all participants in the second Prevalence Study screen was chosen to participate as probands. Basic demographic information was collected and plasma lipids and lipoproteins were measured on all first-degree relatives and spouses of the probands. Data collection was completed in 1978.

The Follow-up Study, a prospective study initiated in mid-1977, will examine the mortality experience of approximately 9,000 males and females who were at least 30 years old at the time of their participation in the second Prevalence Study screen.

### **LRC Program Structure**

Ten North American Lipid Research Clinics participated in the Prevalence Study (Fig. 2). In addition, the following central support agencies were assigned specific tasks:

The Central Patient Registry and Coordinating Center assisted in the scientific design and management of the studies, was responsible for the receipt, editing, verification and quality control, and participated in the analysis of collaborative data.

The Central Electrocardiographic Laboratory was responsible for the visual and computer coding of all exercise and resting electrocardiographic data collected by the LRC's.

The Lipid Standardization Laboratory supplied lipid standards, control serum calibration and external surveillance pools. It also monitored the standardization of lipid and lipoprotein determination methodology at each clinic.


The Central Clinical Chemistry Laboratory performed all non-lipid clinical chemistry determinations.

**The Nutrition Coding Center** coded all 24-hour dietary recalls collected during the second Prevalence Study screen.

### Overview (cont'd.)

Figure 2

North American Lipid Research Clinics and Central Support Agencies



### **Lipid Research Clinics**

Baylor College of Medicine, Houston, Texas
\*George Washington University, Washington, D.C.
Johns Hopkins University, Baltimore, Maryland
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma
Stanford University, Palo Alto, California
University of California at San Diego, La Jolla, California
University of Cincinnati, Cincinnati, Ohio
University of Iowa, Iowa City, Iowa
University of Minnesota, Minneapolis, Minnesota
University of Toronto and McMaster University, Ontario, Canada
University of Washington, Seattle, Washington
\*Washington University, St. Louis, Missouri

### **Central Support Agencies**

Central Patient Registry and Coordinating Center
University of North Carolina, Chapel Hill, North Carolina
Central Electrocardiographic Laboratory
University of Alabama, Birmingham, Alabama
Lipid Standardization Laboratory
Center for Disease Control, Atlanta, Georgia
Central Clinical Chemistry Laboratory
Van Nuys, California
Nutrition Coding Center
University of Minnesota, Minneapolis, Minnesota

<sup>\*</sup>Participation in CPPT only.

### **The Prevalence Study**

### Visit-1 and Visit-2 Screens: Objectives and Descriptions

The Prevalence Study consisted of two screens designated as Visit 1 and Visit 2, and was conducted according to a standardized protocol in well-defined target populations (Fig. 3). Data collection began in 1972 and ended in 1976. The median time between the two screens was 96 days. The population studied by each LRC provided an independent contribution to the epidemiologic data base. The selected populations were diverse and included a broad range of geographic, socio-economic, occupational, age, sex, and ethnic groups (See Table 1). However, these populations were not selected to be a representative sample of the North American population.

### Visit 1. The objectives of Visit 1 were:

- to provide estimates of the prevalence of dyslipidemia in specified populations;
- to investigate the distributions of cholesterol and triglyceride in specified populations; and
- to select participants for Visit 2.

During the Visit-1 screen, a one-page questionnaire collecting identifying and sociodemographic information was completed, and plasma samples were obtained from fasting participants (≥ 12 hours) for cholesterol and triglyceride determinations. The LRC's screened a total of 60,502 eligible participants at Visit 1.

A 15% random sample (N=9,107) of all Visit-1 participants as well as Visit-1 participants who had elevated lipids (N=6,882) or were taking lipid-altering medication (N=346) were asked to return for the Visit-2 screen. These three groups of 16,335 participants represented approximately 25% of all the subjects screened at Visit 1.

### Visit 2. The objectives of Visit 2 were:

- to identify participants with primary or secondary dyslipoproteinemia;
- to determine the prevalence of lipids and lipoprotein patterns and their associations with
   (1) CHD and other vascular diseases and (2) other risk factors for CHD; and
- to determine the relationships between lipids and lipoprotein patterns and selected physiologic, nutritional and sociodemographic variables.

Visit 2, a more comprehensive screening than Visit 1, involved the following procedures:


- Interview. Data were collected on medication usage, medical history of CHD and related disorders.
- 2. **Physical examination.** This was an examination which provided cardiopulmonary information as well as blood pressure and anthropometric indices.
- 3. **ECG.** Resting and graded exercise electrocardiograms were obtained on participants 20 years of age or older and were coded both visually and by computer.
- Clinical Chemistries. Plasma samples were obtained from fasting participants (≥ 12 hours) for the following:
  - a. Lipid and lipoprotein determinations; and
  - b. A battery of non-lipid determinations.
- One-day Dietary Recall. Information was collected for all food and beverage items consumed during the preceding day.

# Table 1. Target and Study Populations (North America).

The Lipid Research Clinics (LRC) Population Studies

	Ж.,							
				VISIT 1		***************************************	VISIT 2	
SAMPLING FRAME	CLINIC NAME	TARGET POPULATION DESCRIPTION	N ELIGIBLE	N SCREENED	RESPONSE RATE, %	N ELIGIBLE	N SCREENED	RESPONSE RATE, %
OCCUPA- TIONAL AND INDUSTRIAL GROUPS	Seattle	Employees of Pacific Northwest Bell Telephone Co. aged 20-65, working in King County as of July 15, 1972.	6,046	4,999	83	1,388	1,191	86
	Stanford	Stanford University employees aged 26-70, working at least half-time as of March 1, 1972.	6,028	4,280	71	1,189	1,074	91
	Toronto- McMaster	Employees of Canadian Bell Telephone Co., Dofasco Steel Foundry, Simpsons Dept. Store and Eatons Dept. Store	11,968	8,208	69	2,182	1,781	82
HOUSEHOLDS	lowa	Adults 25-59 years of age residing in Cedar County, lowa as of July 1, 1973.	5,594	3,918	70	1,099	999	91
	Johns Hopkins	East Baltimore*—residents, as of January 1, 1972, in 11 census tracts in East Baltimore, Md. Columbia—Adults, children and	5,075	2,459* 4,393	— 87	1,145	— 1,041	<u> </u>
		relatives, living in the same household, who were members of the Columbia Medical Plan between 1973-1975.						
	La Jolia	Residents as of August 2, 1972 of Rancho Bernardo, California, aged 12 or more years.	7,791	6,087	78	1,644	1,459	89
	Minnesota	Residents aged 10-59 of 4 census tracts in Richfield, Minnesota between May 1, 1973 and April 30, 1974.	8,392	6,750	80	1,779	1,380	78
	Oklahoma	Residents 18 years and older living in Canadian, McClain, Lincoln or Pottawatomie Counties as of April 1, 1973.	9,522	7,179	75	1,958	1,638	84
SCHOOL CHILDREN AND THEIR PARENTS	Baylor	Sophomore high school students in the Houston Independent School District between 1972-75, and their parents.	5,939	3,795	64	902	637	71
	Cincinnati	Students and their parents enrolled in the Princeton School District during 1973-74 in grades 1, 3, 5, 7, 9, 11 and 12.	15,571	10,893	70	3,049	2,652	87
TOTAL			81,926	60,502	74	16,335	13,852	85

Figure 3
Visit 1 and Visit 2 Response Rates
The LRC Program Prevalence Study
(North America)



### C. Methods

The sociodemographic and physiologic variables presented in this Data Book and brief descriptions of the methodologies used are listed below. Detailed presentations of methodology for the respective variables are presented in references 3 and 4.

### **Lipid and Lipoprotein Determinations:**

### a. Lipids:

Plasma total cholesterol and triglyceride levels were estimated by a two-step method:

- 1) preparation of an isopropanol extract of plasma, and subsequent treatment with a zeolite mixture to remove phospholipids, glucose, and bilirubin; and
- 2) simultaneous determination of cholesterol and triglyceride levels by use of the AutoAnalyzer (AA-I or AA-II).

### b. Lipoproteins:

Lipoproteins were separated by ultracentrifugation at d 1.006 g/ml; the resulting top fraction (d < 1.006 g/ml) contained very-low-density lipoprotein (VLDL) and the bottom fraction (d > 1.006 g/ml), both high-density (HDL) and low-density (LDL) lipoproteins. Lipoprotein fractions were quantified by cholesterol content and expressed as mg lipoprotein-cholesterol/dl plasma. (For the cholesterol estimation procedure, see Lipids.)

**HDL-cholesterol** (HDL-c) was estimated from the supernatant fraction following precipitation of LDL and VLDL from whole plasma by heparin and MnCl<sub>2</sub>.

**LDL-cholesterol** (LDL-c) was calculated as the total cholesterol value in the d>1.006 fraction minus the HDL-cholesterol value.

**VLDL-cholesterol** (VLDL-c) was estimated by subtracting the d > 1.006 fraction cholesterol from plasma total cholesterol.

### **Education of Head of Household**

Education was coded according to the participant's response to the question: "How much education has the head of your household had?"

### Occupation of Head of Household

Participants were classified according to the occupation of the head of the household, which was determined by the participant's response to the question: "What is the usual occupation of your head of household?"

### Smoking

Participants were asked whether they had never smoked cigarettes or were current/past cigarette smokers. Current smokers were also asked the number of cigarettes usually smoked per day.

### **Blood Pressure**

Blood pressure was measured on the right arm, after the participant had been sitting for at least five minutes. Four blood pressure measurements were obtained, two by use of a standard sphygmomanometer and two with a random-zero sphygmomanometer. For each method, the averages of the two readings are presented. Systolic blood pressure was defined by the appearance of sound (Korotkoff's first phase), and diastolic by the disappearance of sound (fifth phase).

### Height

Standing height, without shoes, was measured to the nearest 0.5 cm.

### Weight

Weight was measured to the nearest 0.1 kg in ordinary street clothes without heavy outer garments.

### Skinfold

Two measurements were made of triceps skinfold, to the nearest 0.5 mm. The measurements were made on the back of the right arm at a level midway between the tip of the acromion and the olecranon. The average of the two measurements is presented here.

### Quetelet Index

This body mass index was calculated by use of the equation:

$$\frac{\text{weight (kg)}}{\text{height}^2 \text{ (cm)}} \times 1000$$

### Sex Hormone Usage

Sex hormone usage was ascertained at both the Visit-1 and Visit-2 screens. For Visit 1, such usage was determined by the participant's response to the following question: "Are you taking oral contraceptives, estrogens or pills for hot flashes or to regulate periods?" For Visit 2 the question was: "Have you taken (during the past two weeks) oral contraceptives, pills for hot flashes or pills to regulate periods?"

### **Data Presentation**

### Introduction

This Data Book is the first compilation of variables that were collected during the Visit-1 and Visit-2 examinations of the LRC Prevalence Study.

The data presented here are from the North American LRC's and include all Visit-1 participants, but only the Visit-2 random sample. Data for participants who were recalled to Visit 2 because of elevated lipid values will be published separately.

This document presents data on the following variables:

Visit 1

Plasma Total Cholesterol Plasma Triglyceride

Education of Head of Household Occupation of Head of Household Sex Hormone Usage (Females) Visit 2

Plasma Total Cholesterol Plasma Triglyceride Plasma Lipoproteins (VLDL-c, LDL-c, HDL-c)

Education of Head of Household Occupation of Head of Household Sex Hormone Usage (Females)

Smoking Blood Pressure Height Weight

Triceps Skinfold Quetelet Index

Collaborative efforts are underway to produce detailed analysis of the North American Prevalence Study data and will include cardiovascular and nutritional data as well as clinical chemistries and medication history. Data from the Israeli and Soviet LRC's are still being collected and will also be presented at a later date.

### **Exclusions**

Data exclusions were the result of deviation from conditions specified in the protocol, missing information, and/or insufficient cell sizes.

In Visit 1, data on 1,353 plasma samples that were frozen prior to chemical analysis were excluded, as were 4 participant records with missing information on age, sex and/or race. (These reasons for exclusion did not occur in Visit 2.) For lipid and lipoprotein data, the exclusion criteria were: fasting less than 12 hours (Visit 1, N = 5220; Visit-2 random sample, N = 47) and/or pregnancy (Visit 1, N = 374; Visit -2 random sample, N = 18). Data for pregnant women were excluded from blood pressure and anthropometric presentations.

Data are presented for both white and black Visit-1 participants, but small cell sizes preclude data presentation for blacks in the Visit-2 random sample.

Thus, the final Visit-1 data set includes 53,651 participants for lipid presentations and 59,145 for non-lipid presentations. For the Visit-2 random sample, 7,005 participants are included in the lipid and lipoprotein presentations, 6,071\* in those for blood pressure, 7,023 for anthropometric measurements, and 7,055 in all other presentations.

### **Format of Data Book**

### Introductory tables

The age-, race-, sex-specific distributions of the Visit-1 participants and the Visit-2 random sample participants are shown in Tables 2 and 3. The age- and race-specific distributions, by sex hormone usage, are given in Tables 4 and 5 for female participants.

### **General format**

The basic format of data presentation is age-, race-, sex-specific. Means and selected percentiles are presented for white and black Visit-1 participants and for white Visit-2 random sample participants. Male/female comparisons of medians are also shown.

### Lipids and lipoproteins

For these variables, means, medians and selected percentiles (5th-10th-25th-75th-90th-95th) are shown in the tables. In the figures, however, only means, medians and the 10th and 90th percentiles are presented. For all figures presenting continuous data, the 10th and 90th percentiles are shown, in preference to the 5th and 95th, because of the greater stability of the estimates.

Given the known effect of sex hormone usage on lipid and lipoprotein values, these distributions are also presented by sex hormone usage.

Figures for the lipid and lipoprotein values also include cumulative frequency distributions.

### Other variables

Data included in these tables are: means, medians, and the 10th-25th-75th-90th percentiles. In the figures, means, medians, and the 10th and 90th percentiles are given.

### Minimum cell sizes

The following minimum cell sizes are used in data presentation:

1. 5th and 95th percentiles: N ≥ 100 (lipid/lipoprotein tables only)

2. 10th and 90th percentiles: N ≥ 75

3. 25th and 75th percentiles: N ≥ 50 (tables only)

4. 50th percentile: N ≥ 40
 5. Mean: N ≥ 25

### **Definitions**

Several explanations of the terms used in the tables are indicated.

- 1. Mean: is the arithmetic mean of the total LRC population.
- 2. Range of Mean: indicates the range among Lipid Research Clinics, i.e., the lowest LRC mean value and the highest LRC mean value.
- Range of Standard Error (SE): represents the SE associated with the highest and lowest LRC mean values.



Age, Race, Sex Distributions and Sex Hormone Usage.

Visit 1; Visit 2, Random Sample.

Table 2. Age, Race, Sex Distributions

Visit 1.

The Lipid Research Clinics Prevalence Study (North America).

				_ " ( )				, ,							
		WHITE				BLA	CK		OTHER						
AGE (Years)	MALES N % Row % Col.	FEMALES N % Row Col.	TOTAL N		LES % Row % Col.		IALES % Row % Col.	TOTAL N	M/ N	ALES % Row % Col.	FEN N	MALES % Row % Col.	TOTAL N	MISSING N	TOTAL N
0-4	269 <sup>48.7</sup> 1.0	222 <sup>40.2</sup> 0.8	491	20	3.6 0.9	28	5.1 1.0	48	7	1.3 1.6	6	1.1 1.1	13		552
5-9	1,331 <sup>40.9</sup> 4.8	1,177 36.2 4.4	2,508	357	11.0 15.9	360	11.1 13.3	717	13	0.4 2.9	16	0.5 3.1	29		3,254
10-14	2,404 <sup>42.1</sup> 8.7	2,212 <sup>38.8</sup> 8.2	4,616	540	9.5 24.0	510	8.9 18.8	1,050	25	0.4 5.5	17	0.3 3.2	42		5,708
15-19	2,358 38.6 8.5	2,430 <sup>39.8</sup> 9.1	4,788	636	10.4 28.3	636	10.4 23.4	1,272	26	0.4 5.7	26	0.4 5.0	52		
20-24	1,048 33.6 3.8	1,822 <sup>58.4</sup> 6.8	2,870	39	1.3 1.7	111	3.6 4.1	150	26	0.8 5.7	74	2.4 14.1	100		3,120
25-29	2,425 44.9 8.8	2,581 <sup>47.8</sup> 9.6	5,006	80	1.5 3.6	155	2.9 5.7	235	69	1.3 15.2	93	1.7 17.7	162		5,403
30-34	2,834 48.8 10.2	2,476 <sup>42.7</sup> 9.2	5,310	107	1.8 4.8	244	4.2 9.0	351	66	1.1 14.6	76	1.3 14.5	142		5,803
35-39	2,709 <sup>49.4</sup> 9.8	2,298 <sup>41.9</sup> 8.6	5,007	121	2.2 5.4	233	4.3 8.6	354	74	1.4 16.3	47	0.9 9.0	121		5,482
40-44	2,828 51.7 10.2	2,296 <sup>42.0</sup> 8.6	5,124	112	2.1 5.0	157	2.9 5.8	269	42	0.8 9.3	34	0.6 6.5	76		5,469
45-49	2,594 <sup>49.5</sup> 9.4	2,363 <sup>45.1</sup> 8.8	4,957	94	1.8 4.2	115	2.2 4.2	209	31	0.6 6.8	42	0.8 8.0	73		5,239
50-54	2,389 <sup>50.3</sup> 8.6	2,151 45.3 8.0	4,540	61	1.3 2.7	75	1.6 2.8	136	33	0.7 7.3	42	0.9 8.0	75		4,751
55-59	1,784 <sup>47.9</sup> 6.4	1,843 <sup>49.5</sup> 6.9	3,627	25	0.7 1.1	39	1.1 1.4	64	17	0.5 3.8	17	0.5 3.2	34		3,725
60-64	984 <sup>44.5</sup> 3.6	1,152 <sup>52.1</sup> 4.3	2,136	30	1.4 1.3	22	1.0 0.8	52	13	0.6 2.9	12	0.5 2.3	25		2,213
65-69	810 <sup>46.8</sup> 2.9	869 <sup>50.2</sup> 3.2	1,679	15	0.9 0.7	17	1.0 0.6	32	7	0.4 1.6	12	0.7 2.3	19		1,730
70+	922 <sup>47.6</sup> 3.3	972 <sup>50.2</sup> 3.6	1,894	12	0.6 0.5	16	0.8 0.6	28	4	0.2 0.9	11	0.6 2.1	15		1,937
MISSING	3		3											1	4
Total N	27,692	26,864	54,556	2,2	249	2,	718	4,967	4	53	5	25	978	1	60,502

Table 3. Age, Race, Sex Distributions

Visit 2, Random Sample.

The Lipid Research Clinics Prevalence Study (North America).

	DAGE										
	WHITE	RACE BLACK	OTHER								
AGE (Years)	MALE FEMALE N % Row N % Row % Col.	MALE FEMALE N % Row N % Row % Col.	MALE FEMALE N % Row % Row % Col.	TOTAL N							
0-4	20 45.5 18 40.9 0.5	2 4.6 3 6.8 0.9	1 2.3 0 0.0	44							
5-9	152 41.1 128 34.6 4.2 128 3.7	41 11.1 46 12.4 14.2	1 0.3 2 0.5 1.7 2 3.5	370							
10-14	303 44.4 248 36.4 7.2	59 8.7 67 9.8 24.8 67 20.7	3 0.4 2 0.3 5.1 2 3.5	682							
15-19	308 41.4 300 40.3 8.5 8.7	62 8.3 69 9.3 26.1 21.3	4 0.5 1 0.1 1.8	744							
20-24	118 34.4 201 58.6 5.8	3 0.9 8 2.3 1.3 8 2.5	3 0.9 10 2.9 5.1 10 17.5	343							
25-29	257 41.0 317 50.6 7.1 317 9.2	12	11 1.8 12 1.9 18.6 12 21.1	627							
30-34	404 50.3 341 42.5 11.2 9.9	12 1.5 33 4.1 5.0 10.2	6 0.8 7 0.9 10.2 7 12.3	803							
35-39	372 50.1 307 41.3 10.3 8.9	19 2.6 29 3.9 9.0	10 1.4 6 0.8 17.0 6 10.5	743							
40-44	388 52.1 324 43.5 10.7 9.4	9 1.2 11 1.5 3.4	10 1.3 3 0.4 17.0 3 5.3	745							
45-49	329 47.5 9.1 329 47.5 9.6	5 0.7 17 2.5 2.1 17 5.3	2 0.3 10 1.5 3.4 10 17.5	692							
50-54	343 54.8 260 41.5 7.6	5 0.8 12 1.9 2.1 12 3.7	3 0.5 3 0.5 5.1 3 5.3	626							
55-59	262 <sup>50.0</sup> <sub>7.3</sub> 252 <sup>48.1</sup> <sub>7.3</sub>	2 0.4 5 1.0 1.5	3 0.6 0 0.0	524							
60-64	131 45.5 145 50.4 3.6 145 4.2	4 1.4 5 1.7	2 0.7 1 0.4 1.8	288							
65-69	105 43.9 131 54.8 2.9 131 3.8	2 0.8 1 0.4 0.3	0 0.0 0 0.0	239							
70+	119 <sup>45.3</sup> 143 <sup>54.4</sup> 4.2	1 0.4 0 0.0	0 0.0 0 0.0	263							
Total N	3,611 3,444	238 324	59 57	7,733							

# Table 4. Sex Hormone Usage, Females, By Age and Race

Visit 1.

	WHITE FEMALES									
	USE	RS	NON-L	JSERS	UNKI	NOWN	TOTAL			
AGE (Years)	N	% Row % Col.	N	% Row % Col.	N	% Row % Col.	N			
0-19	204	3.5 3.2	5,646	96.5 28.6	3	0.1 4.9	5,853			
20-29	1,836	42.5 28.5	2,482	57.4 12.6	7	0.2 11.5	4,325			
30-39	1,075	23.2 16.7	3,547	76.7 17.9	3	0.1 4.9	4,625			
40-49	1,184	26.0 18.4	3,360	73.8 17.0	10	0.2 16.4	4,554			
50-59	1,399	35.3 21.7	2,544	64.2 12.9	18	0.5 29.5	3,961			
60+	746	25.2 11.6	2,199	74.2 11.1	20	0.7 32.8	2,965			
Total N	N 6,444 19,778		778	(	61	26,283				

	USI	ERS	NON-L	JSERS	UNK	NOWN	TOTAL
AGE (Years)	N	% Row % Col.	N	% Row % Col.	N	% Row % Col.	N
0-19	73	5.0 21.4	1,387	94.9 61.8	1	0.1 20.0	1,461
20-29	114	43.2	150	56.8	0	0.0	264
		33.3		6.7		0.0	
30-39	99	22.3 29.0	343	77.3 15.3	2	0.5 40.0	444
40-49	44	17.1 12.9	213	82.6 9.5	1	0.4 20.0	258
50-59	12	11.0 3.5	97	90.0 4.3	0	0.0 0.0	109
60+	0	0.0 0.0	54	98.2 2.4	1	1.8 20.0	55
Total N	34	42	2,2	44		5	2,591

The LRC Prevalence Study (North America).

# Table 5. Sex Hormone Usage, White Females, by Age

Visit 2, Random Sample.

The LRC Program Prevalence Study (North America).

			4.0				
				WHITE FE	EMALES	;	
	US	ERS	NON-	JSERS	UNK	NOWN	TOTAL
AGE (Years)	N	% Row % Col.	N	% Row % Col.	N	% Row % Col.	N
0-19	20	2.9 2.7	673	97.0 25.6	1	0.1 1.3	694
20-29	234	45.2 31.8	281	54.3 10.7	3	0.6 4.0	518
30-39	148	22.8 20.1	488	75.3 18.5	12	1.9 16.0	648
40-49	136	20.8 18.5	498	76.3 18.9	19	2.9 25.3	653
50-59	131	25.6 17.8	353	69.0 13.4	28	5.5 37.3	512
60+	67	16.0 9.1	340	81.2 12.9	12	2.9 16.0	419
Total N	7	36	2,633			75	3,444





Plasma Lipids and Lipoproteins (mg/dl) by Age, Race, Sex and Hormone Usage. Means and Selected Percentiles.

A. Visit 1.

Table 6. Plasma Total Cholesterol (mg/dl)

White Males - Visit 1.

The LRC Prevalence Study (North America).

		-1									
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES			
				5	10	25	50	75	90	95	
0-4	238	154.6 ± 1.8	154.4 ± 2.0 155.1 ± 3.7	114	125	137	151	171	186	203	
5-9	1253	159.9 ± 0.7	154.5 ± 1.4 161.7 ± 0.9	121	130	143	159	175	191	203	
10-14	2278	157.6 ± 0.5	$154.0 \pm 1.5$ $160.4 \pm 2.4$	119	127	140	155	173	190	202	
15-19	1980	149.9 ± 0.6	$145.0 \pm 2.1$ $154.2 \pm 2.9$	113	120	132	146	165	183	197	
20-24	882	166.5 ± 1.0	156.7 ± 4.1 168.0 ± 2.0	124	130	146	165	186	204	218	
25-29	2042	182.2 ± 0.8	173.4 ± 2.7 187.4 ± 2.6	133	143	159	178	202	227	244	
30-34	2444	192.2 ± 0.7	180.1 ± 2.2 197.0 ± 1.7	138	148	167	190	213	239	254	
35-39	2320	201.3 ± 0.8	191.1 ± 2.9 209.9 ± 2.5	146	157	176	197	223	249	270	
40-44	2428	206.5 ± 0.8	195.6 ± 3.6 212.8 ± 2.6	151	163	182	203	228	250	268	
45-49	2296	212.2 ± 0.8	199.9 ± 4.2 217.4 ± 2.3	158	169	188	210	234	258	276	
50-54	2138	212.7 ± 0.8	207.2 ± 5.2 219.5 ± 4.2	158	169	187	210	235	261	277	
55-59	1621	213.9 ± 1.0	209.6 ± 2.4 217.4 ± 2.4	156	167	189	212	235	262	276	
60-64	905	213.0 ± 1.2	207.3 ± 2.9 220.2 ± 2.9	159	171	188	210	235	259	276	
65-69	750	212.6 ± 1.3	210.0 ± 2.5 217.7 ± 6.3	158	170	190	210	233	258	274	
70+	850	206.8 ± 1.2	202.9 ± 2.5 208.3 ± 1.4	151	162	182	205	229	252	270	

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

### Table 7. Plasma Total Cholesterol (mg/dl)

White Females (Total) - Visit 1.

The LRC Prevalence Study (North America).

1											
	AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
	(100.0)				5	10	25	50	75	90	95
	0-4	186	156.0 ± 2.0	155.6 ± 2.1 158.0 ± 5.2	112	120	139	156	172	189	200
	5-9	1118	163.7 ± 0.7	159.8 ± 1.5 167.7 ± 2.2	126	134	146	163	179	195	205
	10-14	2087	159.6 ± 0.5	156.2 ± 1.6 161.0 ± 2.2	124	131	144	158	174	190	201
	15-19	2079	157.6 ± 0.6	155.4 ± 1.0 164.6 ± 2.5	120	127	140	155	172	191	203
	20-24	1566	171.7 ± 0.8	165.8 ± 5.8 173.1 ± 2.1	125	134	149	170	190	214	228
	25-29	2189	175.8 ± 0.6	166.2 ± 2.4 181.9 ± 1.9	130	140	155	173	193	216	229
	30-34	2151	179.0 ± 0.7	171.8 ± 2.1 186.6 ± 2.3	131	141	158	176	196	222	238
	35-39	2012	186.4 ± 0.7	177.2 ± 2.4 190.5 ± 2.7	141	148	164	183	205	228	245
	40-44	2050	195.0 ± 0.8	187.6 ± 4.0 198.6 ± 2.8	147	155	171	192	215	237	253
	45-49	2149	204.5 ± 0.8	195.4 ± 4.2 210.1 ± 2.7	152	161	178	201	226	251	268
	50-54	1992	217.9 ± 0.8	209.0 ± 4.7 220.7 ± 2.3	163	173	192	215	240	266	285
	55-59	1698	226.3 ± 0.9	220.6 ± 3.3 230.7 ± 2.2	169	181	200	223	248	276	294
	60-64	1070	228.6 ± 1.2	225.2 ± 3.5 232.1 ± 5.3	173	183	202	226	252	278	296
	65-69	822	229.9 ± 1.4	229.4 ± 1.7 231.9 ± 6.7	171	183	205	226	252	277	297
	70+	888	226.0 ± 1.4	224.6 ± 2.6 226.9 ± 1.6	167	180	199	224	251	276	288

Note: Mean not given if N < 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

### Table 8. Plasma Total Cholesterol (mg/dl)

White Females (Sex Hormone Users) – Visit 1. The LRC Prevalence Study (North America).

	ū									
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
,				5	10	25	50	75	90	95
0-4	0	<del></del>	<del>_</del>		_		_		_	_
5-9	0	_					_	_	_	
10-14	7			II —	-			_		
15-19	167	169.0 ± 2.5	155.8 ± 5.4 178.8 ± 4.6	121	131	144	165	189	207	231
20-24	788	179.2 ± 1.1	177.6 ± 1.7 183.7 ± 3.6	131	143	158	178	197	221	236
25-29	855	183.6 ± 1.0	173.3 ± 5.0 193.1 ± 4.9	141	147	163	182	201	224	236
30-34	579	188.5 ± 1.4	181.3 ± 5.4 193.7 ± 4.2	139	150	166	184	209	237	246
35-39	406	194.4 ± 1.6	$184.7 \pm 4.8$ $199.9 \pm 5.8$	146	154	169	191	215	239	249
40-44	466	199.4 ± 1.6	$190.6 \pm 6.5$ $204.1 \pm 4.3$	152	160	177	195	219	241	258
45-49	627	209.4 ± 1.6	201.2 ± 6.7 216.6 ± 4.8	155	163	183	204	234	256	276
50-54	729	218.1 ± 1.4	211.7 ± 2.8 224.4 ± 5.5	167	175	192	216	239	261	279
55-59	577	218.1 ± 1.4 223.4 ± 4.8	214.2 ± 2.7	164	175	194	215	240	262	283
60-64	341	224.4 ± 2.0	217.0 ± 5.5 227.3 ± 4.2	172	182	200	221	246	268	285
65-69	224	222.5 ± 2.2	222.6 ± 2.4 224.1 ± 5.1	173	184	200	221	243	264	279
70+	132	215.9 ± 2.8	215.6 ± 3.0 215.6 ± 3.0	160	176	196	213	235	258	274

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

### Table 9. Plasma Total Cholesterol (mg/dl)

White Females (Non-Sex Hormone Users) – Visit 1. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(Teals)		Mean ± O.L.	Mean ± O.L.	5	10	25	50	75	90	95
0-4	186	156.0 ± 2.0	155.6 ± 2.1 158.0 ± 5.2	112	120	139	156	172	189	200
5-9	1118	163.7 ± 0.7	159.8 ± 1.5 167.7 ± 2.2	126	134	146	163	179	195	205
10-14	2080	159.6 ± 0.5	156.2 ± 1.6 161.2 ± 2.2	124	131	144	158	174	190	201
15-19	1911	156.6 ± 0.6	155.3 ± 1.1 163.7 ± 2.5	120	126	139	154	171	190	200
20-24	778	164.1 ± 1.1	160.8 ± 5.9 166.1 ± 1.9	122	130	143	160	182	203	216
25-29	1329	170.7 ± 0.8	163.6 ± 2.8 180.1 ± 2.5	128	136	151	168	187	209	222
30-34	1569	175.4 ± 0.8	169.4 ± 2.2 182.7 ± 2.8	130	139	154	172	193	213	231
35-39	1606	184.4 ± 0.8	$174.6 \pm 2.4$ $190.2 \pm 3.1$	140	147	163	182	202	225	242
40-44	1583	193.8 ± 0.9	189.1 ± 4.4 197.9 ± 3.2	147	154	170	191	214	235	252
45-49	1515	202.5 ± 1.0	$197.2 \pm 5.5$ $210.6 \pm 4.3$	152	161	177	199	224	247	265
50-54	1257	217.7 ± 1.1	204.9 ± 6.2 222.4 ± 3.9	162	172	192	215	241	268	285
55-59	1112	230.5 ± 1.2	223.6 ± 4.5 241.4 ± 3.6	173	183	204	228	253	282	300
60-64	723	230.8 ± 1.5	222.8 ± 5.5 233.6 ± 2.6	172	186	203	228	254	280	297
65-69	593	232.8 ± 1.7	233.0 ± 2.2 233.6 ± 2.9	171	183	208	229	256	280	303
70+	748	228.1 ± 1.5	225.9 ± 2.7 229.8 ± 1.8	169	180	200	226	253	278	289

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

## Table 10. Plasma Total Cholesterol (mg/dl)

Black Males - Visit 1.

The LRC Prevalence Study (North America).

						V					
AGE (Years)	Ν	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.	PERCENTILES							
				5	10	25	50	75	90	95	
0-9	351	165.6 ± 1.5	158.0 ± 3.5 167.0 ± 1.6	129	134	148	162	182	201	214	
10-19 1	000	160.4 ± 0.8	155.2 ± 3.8 162.6 ± 1.1	120	129	142	158	177	195	205	
20-29	97	178.5 ± 3.7	177.3 ± 7.0 177.3 ± 7.0	, <del>-</del>	132	156	177	196	220	_	
30-39	178	191.6 ± 2.8	179.9 ± 6.2 196.5 ± 7.0	138	146	163	190	213	234	253	
40-49	167	206.9 ± 3.0	192.9 ± 8.5 218.0 ± 5.2	148	156	178	209	230	254	267	
50-59	70	206.5 ± 4.5	210.1 ± 5.7 210.1 ± 5.7			182	200	227		_	
60+	46	220.7 ± 5.6	229.8 ± 7.6 229.8 ± 7.6	<u> </u>	_	_	221	_	_	_	

Note: Mean not given if N < 25;
5th and 95th percentiles not given if N < 100;
10th and 90th percentiles not given if N < 75;
25th and 75th percentiles not given if N < 50;
50th percentile not given if N < 40.

### Table 11. Plasma Total Cholesterol (mg/dl)

Black Females (Total) - Visit 1.

The LRC Prevalence Study (North America).

AGE N (Years)	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E. –		PERCENTILES							
(10013)	WC411 = 0.L.	Would - O.E.	5	10	25	50	75	90	95		
0-9 362	171.3 ± 1.6	160.1 ± 4.1 173.5 ± 1.7	128	136	150	170	186	211	222		
10-19 991	165.0 ± 0.9	159.1 ± 3.9 165.9 ± 1.1	124	131	146	163	182	202	211		
20-29 233	177.3 ± 2.2	174.6 ± 3.1 182.9 ± 5.7	124	139	154	174	194	220	235		
30-39 381	185.0 ± 1.8	175.2 ± 4.2 192.4 ± 9.7	132	144	162	182	206	232	243		
40-49 227	201.6 ± 2.5	$190.8 \pm 6.5$ $213.9 \pm 7.3$	146	160	176	198	220	245	268		
50-59 90	217.3 ± 4.3	218.7 ± 5.8 218.7 ± 5.8		174	187	209	238	274			
60+ 49	234.3 ± 6.7	238.2 ± 11.0 238.2 ± 11.0	-			229		_			

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.


### Table 12. Plasma Total Cholesterol (mg/dl)

Black Females, by Sex Hormone Usage – Visit 1. The LRC Prevalence Study (North America).


	,	ď			- 3	-	-				
AGE (Years)	N	OVERALL Mean ± S.E.	PERCENTILES								
(100.0)		100011 = 0.2.	5	10	25	50	75	90	95		
		SEX	HORM	ONE US	SERS						
0-9	0-9 0 — — — — — — —										
10-19	62	168.9 ± 3.7			149	168	187				
20-29	104	176.3 ± 3.4	124	137	149	171	197	220	234		
30-39	88	180.9 ± 3.5		144	160	172	203	226	_		
40-49	38	201.9 ± 6.1	-					_	_		
50-59	10		_	_		_	_	_	_		
60+	0			<del></del>							
		NON-S	EX HOF	RMONE	USERS	3					
0-9	362	171.3 ± 1.6	128	136	150	170	186	211	222		
10-19	929	164.7 ± 0.9	124	131	146	162	182	201	211		
20-29	129	178.1 ± 3.0	125	139	156	176	194	218	234		
30-39	291	186.4 ± 2.1	132	144	165	185	207	233	243		
40-49	188	201.8 ± 2.8	145	160	175	198	220	246	267		
50-59	80	215.5 ± 4.5		174	186	208	236	273			
60+	48	233.6 ± 6.8		_		224					

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Plasma Total Cholesterol (mg/dl)



Visit 1.




50th percentile not given if N < 40.

36

# Plasma Total Cholesterol (mg/dl) Cumulative Frequencies

Visit 1.



#### Plasma Total Cholesterol (mg/dl)

Visit 1.

The LRC Prevalence Study (North America).




Figure 18
Blacks (40-59 Years)




Table 13. Plasma Triglyceride (mg/dl)

White Males - Visit 1.

The LRC Prevalence Study (North America).

									_	
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	TILES		
				5	10	25	50	75	90	95
0-4	238	56.4 ± 1.6	55.0 ± 1.8 61.1 ± 2.9	29	33	40	51	67	84	99
5-9	1253	55.7 ± 0.6	50.9 ± 1.4 60.5 ± 1.8	30	33	40	51	65	85	101
10-14	2278	65.6 ± 0.6	56.5 ± 1.8 68.5 ± 0.9	32	37	45	59	78	102	125
15-19	1980	78.0 ± 0.9	63.9 ± 2.8 87.6 ± 4.3	37	43	54	69	91	120	148
20-24	882	100.3 ± 1.9	$73.4 \pm 4.4$ $107.8 \pm 4.9$	44	50	63	86	119	165	201
25-29	2042	115.8 ± 2.3	$94.6 \pm 4.8$ $130.9 \pm 4.5$	46	54	70	95	136	199	249
30-34	2444	128.3 ± 2.5	$97.4 \pm 3.9$ $144.8 \pm 4.7$	50	58	75	104	149	213	266
35-39	2320	144.9 ± 2.5	129.6 ± 6.5 155.8 ± 4.4	54	62	81	113	170	251	321
40-44	2428	151.4 ± 3.0	$127.8 \pm 6.0$ $167.3 \pm 6.9$	55	64	86	122	174	248	320
45-49	2296	151.7 ± 2.4	139.5 ± 8.7 176.3 ± 16.1	58	68	89	124	174	253	327
50-54	2138	151.8 ± 2.5	$138.6 \pm 5.7$ $170.4 \pm 13.1$	58	68	87	124	180	250	320
55-59	1621	141.4 ± 2.2	125.5 ± 5.1 151.5 ± 18.0	58	67	87	119	170	235	286
60-64	905	142.3 ± 3.1	$128.8 \pm 4.4$ $156.3 \pm 17.0$	58	68	87	119	169	235	291
65-69	750	136.7 ± 5.2	99.1 ± 6.6 141.9 ± 10.6	57	64	83	112	149	208	267
70+	850	129.8 ± 2.7	$127.2 \pm 2.8$ $137.0 \pm 6.8$	58	67	83	111	149	212	258

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

Table 14. Plasma Triglyceride (mg/dl)

White Females (Total) - Visit 1.

The LRC Prevalence Study (North America).

						. ,				
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		·
				5	10	25	50	75	90	95
0-4	186	63.9 ± 1.8	62.6 ± 2.0 69.9 ± 4.0	34	38	45	59	77	96	112
5-9	1118	60.3 ± 0.8	52.8 ± 1.5 65.7 ± 2.0	32	36	44	55	71	90	105
10-14	2087	75.4 ± 0.7	67.4 ± 2.1 81.3 ± 2.1	37	44	54	70	90	114	131
15-19	2079	75.2 ± 0.8	$68.8 \pm 2.1$ $100.7 \pm 5.8$	39	44	53	68	87	114	132
20-24	1566	89.0 ± 1.1	75.5 ± 4.5 96.3 ± 2.9	40	47	60	81	108	141	165
25-29	2189	88.7 ± 1.0	$73.9 \pm 2.1$ $100.3 \pm 3.0$	40	46	58	78	107	142	172
30-34	2151	88.5 ± 1.0	76.6 ± 3.1 100.6 ± 3.0	41	46	58	77	106	146	176
35-39	2012	94.3 ± 1.2	$76.9 \pm 3.6$ $109.0 \pm 3.9$	41	47	60	80	113	160	194
40-44	2050	105.3 ± 1.8	91.0 ± 7.1 119.9 ± 7.5	47	54	65	88	122	170	209
45-49	2149	111.8 ± 1.7	87.1 ± 5.3 123.3 ± 4.6	47	54	69	94	132	184	228
50-54	1992	120.4 ± 1.8	92.4 ± 7.5 144.9 ± 7.5	54	61	77	101	141	192	238
55-59	1698	125.7 ± 1.8	$101.3 \pm 3.7$ $145.3 \pm 4.7$	56	65	81	108	148	203	257
60-64	1070	126.5 ± 2.5	100.3 ± 4.3 150.8 ± 7.2	57	64	81	108	148	201	240
65-69	822	130.6 ± 3.5	115.3 ± 13.6 149.0 ± 8.6	60	66	83	112	157	203	241
70+	888	131.0 ± 3.4	119.0 ± 3.2 149.7 ± 7.1	60	69	85	111	150	203	235

Note: Mean not given if  $N \simeq 25$ ; 5th and 95th percentiles not given if  $N \le 100$ ; 10th and 90th percentiles not given if  $N \le 75$ ; 25th and 75th percentiles not given if  $N \le 50$ ; 50th percentile not given if  $N \le 40$ .

#### Table 15. Plasma Triglyceride (mg/dl)

White Females (Sex Hormone Users) – Visit 1. The LRC Prevalence Study (North America).

	•				-			-		
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
				5	10	25	50	75	90	95
0-4	0		_				_	_	_	_
5-9	0	_	<del></del>			_				_
10-14	7	_	<del>-</del>			-		_	_	
15-19	167	106.3 ± 3.9	86.5 ± 6.0 118.8 ± 9.4	49	54	74	95	127	162	200
20-24	788	105.3 ± 1.5	$96.9 \pm 2.0$ $115.2 \pm 3.6$	55	63	79	98	125	155	176
25-29	855	110.4 ± 1.6	92.3 ± 3.9 121.5 ± 4.9	57	64	78	101	129	164	191
30-34	579	115.8 ± 2.0	$104.3 \pm 7.7$ $129.3 \pm 6.6$	58	67	83	106	138	179	206
35-39	406	126.0 ± 2.9	110.7 ± 11.3 141.0 ± 12.4	56	66	86	112	154	200	241
40-44	466	128.9 ± 3.4	$109.7 \pm 7.3$ $149.7 \pm 12.2$	58	67	84	113	150	205	237
45-49	627	129.6 ± 3.6	$112.0 \pm 5.8$ $166.2 \pm 22.7$	53	63	81	111	154	210	260
50-54	729	130.0 ± 3.6	118.2 ± 5.9 160.7 ± 15.2	57	65	83	110	152	200	248
55-59	577	126.5 ± 2.7	106.2 ± 5.6 136.3 ± 7.3	62	68	87	110	148	203	238
60-64	341	126.0 ± 3.5	99.8 ± 6.6 133.7 ± 9.0	57	64	83	112	146	197	240
65-69	224	129.5 ± 4.4	126.5 ± 5.5 140.8 ± 7.8	60	65	83	110	165	201	234
70+	132	121.1 ± 4.4	119.2 ± 4.6 119.2 ± 4.6	60	67	82	109	148	191	216

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 16. Plasma Triglyceride (mg/dl)

White Females (Non-Sex Hormone Users) – Visit 1. The LRC Prevalence Study (North America).

	÷. ==									
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
	-			5	10	25	50	75	90	95
0-4	186	63.9 ± 1.8	62.6 ± 2.0 69.9 ± 4.0	34	38	45	59	77	96	112
5-9	1118	60.3 ± 0.8	52.8 ± 1.5 65.7 ± 2.0	32	36	44	55	71	90	105
10-14	2080	75.4 ± 0.7	67.4 ± 2.1 81.3 ± 2.1	37	44	54	70	90	114	131
15-19	1911	72.4 ± 0.7	65.8 ± 1.8 90.3 ± 7.2	39	44	52	66	84	107	124
20-24	778	72.4 ± 1.3	64.1 ± 1.7 79.7 ± 4.1	36	41	51	64	84	112	131
25-29	1329	74.7 ± 1.0	62.4 ± 1.8 89.1 ± 3.6	37	42	51	65	86	116	145
30-34	1569	78.5 ± 1.0	68.2 ± 2.5 89.1 ± 2.9	39	44	54	69	91	123	151
35-39	1606	86.3 ± 1.2	69.1 ± 3.0 99.5 ± 4.7	40	46	57	73	101	137	176
40-44	1583	98.4 ± 2.1	85.0 ± 9.0 113.3 ± 8.7	45	51	62	82	111	155	191
45-49	1515	104.5 ± 1.8	83.2 ± 5.5 119.6 ± 7.3	46	53	65	87	119	171	214
50-54	1257	114.8 ± 2.0	102.7 ± 7.1 132.7 ± 16.0	52	59	74	97	135	186	233
55-59	1112	125.0 ± 2.3	97.9 ± 4.9 149.1 ± 5.8	55	63	79	106	149	204	262
60-64	723	127.0 ± 3.3	100.8 ± 5.4 157.4 ± 9.3	56	64	80	105	150	202	239
65-69	593	131.3 ± 4.5	117.5 ± 2.9 151.1 ± 10.6	60	66	84	112	153	204	243
70+	748	132.4 ± 3.9	119.0 ± 3.9 150.5 ± 7.6	60	69	86	111	150	204	237

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 17. Plasma Triglyceride (mg/dl)

Black Males - Visit 1.

The LRC Prevalence Study (North America).

	45								-	
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(10013)		Wearr = O.E.	Wicarr = O.E.	5	10	25	50	75	90	95
0-9	351	52.3 ± 1.0	50.0 ± 2.9 52.7 ± 1.1	31	34	40	47	60	75	88
10-19	1000	58.6 ± 0.8	50.2 ± 4.3 60.5 ± 1.1	31	35	42	53	67	88	102
20-29	97	81.3 ± 4.5	82.4 ± 8.9 82.4 ± 8.9		43	52	71	88	125	_
30-39	178	106.9 ± 4.6	94.8 ± 8.8 117.2 ± 7.6	42	50	69	91	128	166	224
40-49	167	126.1 ± 7.0	115.8 ± 18.6 148.2 ± 27.3	52	62	79	97	138	215	294
50-59	70	142.2 ± 14.9	135.6 ± 12.7 135.6 ± 12.7			72	105	150		_
60+	46	108.5 ± 7.1	105.2 ± 8.5 105.2 ± 8.5				96		-	-

Note: Mean not given if N = 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Table 18. Plasma Triglyceride (mg/dl)

Black Females (Total) – Visit 1. The LRC Prevalence Study (North America).

-					_					
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
				5	10	25	50	75	90	95
0-9	362	55.7 ± 1.2	52.8 ± 4.0 56.3 ± 1.3	33	35	41	50	63	83	94
10-19	991	64.6 ± 0.8	58.6 ± 3.4 66.8 ± 1.0	36	39	47	60	76	95	110
20-29	233	76.6 ± 2.4	72.0 ± 3.3 88.8 ± 6.2	38	42	53	68	92	118	137
30-39	381	80.4 ± 1.9	64.6 ± 4.0 86.8 ± 2.8	38	43	53	74	95	129	150
40-49	227	98.5 ± 5.9	87.2 ± 10.9 136.8 ± 42.1	43	49	60	84	109	153	188
50-59	90	104.4 ± 5.5	108.2 ± 5.6 108.2 ± 5.6		52	71	94	124	176	
60+	49	119.7 ± 7.9	127.6 ± 13.8 127.6 ± 13.8				106			

Note: Mean not given if N < 25, 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 19. Plasma Triglyceride (mg/dl)

Black Females by Sex Hormone Usage – Visit 1. The LRC Prevalence Study (North America).


AGE	N	OVERALL			PEF	RCENTII	LES		
(Years)		Mean ± S.E.	5	10	25	50	75	90	95
		HC	RMON	IE USER	S				
0-9	0		_	_	_	-	_	_	_
10-19	62	84.9 ± 5.1	_	_	66	77	92	_	_
20-29	104	83.1 ± 3.1	41	50	60	76	102	122	143
30-39	88	93.8 ± 4.2	_	51	67	87	116	146	_
40-49	38	116.3 ± 10.5	_	_	_	_	_	_	_
50-59	10	<del></del>	_	_	_	_		_	_
60+	0		_	_		_	_	_	_
		NON-	HORM	ONE US	ERS				
0-9	362	55.7 ± 1.2	33	35	41	50	63	83	94
10-19	929	63.2 ± 0.8	36	39	46	58	74	94	108
20-29	129	$71.3 \pm 3.5$	36	42	48	60	80	110	127
30-39	291	76.4 ± 2.1	38	42	51	69	89	124	140
40-49	188	95.1 ± 6.7	43	47	58	80	105	150	175
50-59	80	102.1 ± 5.9	_	50	67	89	122	162	
60+	48	115.4 ± 6.7	_	_	_	103	_		_

Note: Mean not given if  $N \leq 25$ ; 5th and 95th percentiles not given if  $N \leq 100$ ; 10th and 90th percentiles not given if  $N \leq 75$ ; 25th and 75th percentiles not given if  $N \leq 50$ ; 50th percentile not given if  $N \leq 40$ .

#### Plasma Triglyceride (mg/dl)

Visit 1.

The LRC Prevalence Study (North America).



50th percentile not given if N < 40.

# Plasma Triglyceride (mg/dl)

Visit 1.

The LRC Prevalence Study (North America).



Means and Selected Percentiles.




Figure 24
Black Females (Total)

Means and Selected Percentiles.





Figure 25 Black Females

Comparison of Medians by Sex Hormone Usage.


Figure 26
Black Males/Black Females (Total)
Comparison of Medians.



10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.


# Plasma Triglyceride (mg/dl) Cumulative Frequencies Visit 1.

The LRC Prevalence Study (North America).



# Plasma Triglyceride (mg/dl) Cumulative Frequencies

The LRC Prevalence Study (North America).



350 400

50

Plasma Triglyceride (mg/dl)

Figure 33 Blacks (40-59 Years)

100

Plasma Triglyceride (mg/dl)


150

200

250

300

50







Plasma Lipids and Lipoproteins (mg/dl) by Age, Race, Sex and Hormone Usage. Means and Selected Percentiles.

B. Visit 2, Random Sample.

#### Table 20. Plasma Total Cholesterol (mg/dl)

White Males - Visit 2, Random Sample.

The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(TCa13)		IVICALI - J.L.	Wear ± 3.E.	5	10	25	50	75	90	95
0-4	20							_		_
5-9	148	155.3 ± 1.8	151.0 ± 3.4 157.3 ± 2.3	125	131	141	153	168	183	189
10-14	299	160.9 ± 1.5	152.0 ± 3.3 168.1 ± 4.3	124	132	144	161	173	191	204
15-19	299	153.1 ± 1.4	150.6 ± 2.6 155.6 ± 2.4	118	123	136	152	168	183	191
20-24	118	162.2 ± 2.5	163.0 ± 5.6 163.5 ± 3.2	118	126	142	159	179	197	212
25-29	253	178.7 ± 2.1	171.3 ± 4.1 187.8 ± 4.7	130	137	154	176	199	223	234
30-34	403	193.1 ± 1.8	185.6 ± 4.6 204.1 ± 5.9	142	152	171	190	213	237	258
35-39	372	200.6 ± 1.9	186.6 ± 4.5 214.5 ± 6.4	147	157	176	195	222	248	267
40-44	385	205.2 ± 1.9	197.8 ± 4.7 210.3 ± 5.8	150	161	179	204	229	251	260
45-49	327	213.4 ± 1.9	201.0 ± 3.9 237.4 ± 7.1	163	171	188	210	234	258	275
50-54	340	213.2 ± 1.9	201.4 ± 7.4 225.4 ± 4.4	156	168	189	211	237	263	274
55-59	261	215.0 ± 2.2	206.8 ± 4.7 227.1 ± 7.2	161	172	188	214	236	260	280
60-64	131	216.6 ± 3.3	216.4 ± 7.4 234.9 ± 7.2	163	170	191	215	237	262	287
65-69	105	221.0 ± 3.8	211.8 ± 6.6 225.7 ± 5.1	166	174	192	213	250	275	288
70+	119	210.3 ± 3.4	210.4 ± 4.1 210.4 ± 4.1	144	160	185	214	236	253	265

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 21. Plasma Total Cholesterol (mg/dl)

White Females (Total) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.	adamata in construction of	Manda and Manda and Andrews Andrews	PER	CENT	ILES		
	PA-PA-AA-A			5	10	25	50	75	90	95
0-4	18	_			_			-	_	_
5-9	126	164.0 ± 1.8	162.1 ± 2.1 167.7 ± 3.6	131	135	150	164	177	189	197
10-14	248	160.1 ± 1.5	157.1 ± 4.0 161.8 ± 4.1	125	131	142	159	171	191	205
15-19	297	159.5 ± 1.6	153.7 ± 5.6 160.4 ± 2.8	119	126	140	157	176	198	208
20-24	199	170.3 ± 2.5	162.8 ± 6.0 176.6 ± 5.8	121	132	147	165	186	220	237
25-29	314	179.5 ± 1.7	169.5 ± 4.6 189.1 ± 4.7	130	142	158	178	198	217	231
30-34	337	179.2 ± 1.7	171.9 ± 4.1 185.6 ± 4.6	133	141	158	178	199	215	227
35-39	300	189.6 ± 2.1	$176.8 \pm 5.6$ $203.4 \pm 7.0$	139	149	165	186	209	233	249
40-44	319	197.5 ± 1.9	188.3 ± 5.4 200.6 ± 6.5	146	156	172	193	220	241	259
45-49	329	206.2 ± 2.0	192.2 ± 7.0 216.5 ± 5.3	148	162	182	204	231	256	268
50-54	257	217.3 ± 2.4	209.9 ± 6.4 223.7 ± 7.7	163	171	188	214	240	267	281
55-59	251	228.7 ± 2.4	225.8 ± 6.3 237.2 ± 7.4	167	182	201	229	251	278	294
60-64	145	232.3 ± 3.7	225.2 ± 5.9 234.3 ± 6.3	172	186	207	226	251	282	300
65-69	130	234.1 ± 4.0	235.0 ± 9.3 235.6 ± 4.2	167	179	212	233	259	282	291
70+	143	224.5 ± 2.8	219.6 ± 3.6 228.2 ± 4.1	173	181	196	226	249	268	280

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 22. Plasma Total Cholesterol (mg/dl)

White Females (Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(10410)		1110an = 0.2.	Would = O.E.	5	10	25	50	75	90	95
0-4	0	_	<del></del>	_	_	_	_	_	_	
5-9	0	<u> </u>	<del>-</del>	<del></del>		_	_		_	
10-14	0	_	<del></del>		_	_	_	_	_	
15-19	20		<del></del>	, <del>-</del>	)	_	_	_	_	_
20-24	101	178.0 ± 3.4	173.8 ± 5.5 178.2 ± 5.3	132	140	156	170	196	224	246
25-29	132	187.2 ± 2.6	182.5 ± 4.9 187.0 ± 6.6	138	151	167	184	206	224	236
30-34	97	190.7 ± 3.3	_		150	170	188	210	231	_
35-39	50	195.6 ± 6.1		_	_	166	196	214	_	
40-44	63	202.9 ± 5.0	<del></del>	_	_	167	201	232	_	_
45-49	72	211.8 ± 4.2	<del></del>		_	184	212	232	_	
50-54	70	205.9 ± 3.5	<del></del>		_	185	207	226	_	
55-59	60	222.4 ± 4.9			_	195	214	244		
60-64	32	220.2 ± 5.2	_				_	_	_	
65-69	25	218.0 ± 5.9	<del>-</del>	, <del></del>	_	_	_			
70+	10		_	<u>'</u> —	_	_				_

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 23. Plasma Total Cholesterol (mg/dl)

White Females (Non-Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).


	75								-	
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
				5	10	25	50	75	90	95
0-4	18		- Andreadories	_	-	_	_	_	_	_
5-9	126	164.0 ± 1.8	162.1 ± 2.1 167.7 ± 3.6	131	135	150	164	177	189	197
10-14	248	160.1 ± 1.5	157.1 ± 4.0 161.8 ± 4.1	125	131	142	159	171	191	205
15-19	276	158.3 ± 1.6	153.3 ± 5.8 160.6 ± 4.6	120	127	140	156	173	195	202
20-24	96	162.1 ± 3.4	164.6 ± 6.4 164.6 ± 6.4	_	124	136	161	176	202	_
25-29	181	173.9 ± 2.2	163.6 ± 5.8 176.1 ± 4.8	129	140	153	173	192	213	222
30-34	235	174.8 ± 1.9	169.3 ± 4.9 182.7 ± 5.9	132	139	154	174	194	211	220
35-39	243	187.5 ± 2.2	186.2 ± 6.3 195.8 ± 5.9	139	148	164	184	208	228	249
40-44	245	196.1 ± 2.1	187.2 ± 5.8 198.2 ± 8.8	149	160	172	191	218	238	252
45-49	249	204.3 ± 2.3	202.4 ± 6.9 215.5 ± 6.1	147	161	180	199	228	253	267
50-54	178	222.7 ± 3.1	$218.6 \pm 7.7$ $231.9 \pm 10.0$	163	174	192	219	248	270	293
55-59	172	232.0 ± 3.0	226.1 ± 9.4 240.2 ± 7.4	169	186	206	232	253	278	297
60-64	111	235.7 ± 4.6	226.2 ± 7.0 242.3 ± 8.4	168	185	209	232	253	289	306
65-69	101	239.6 ± 4.6	240.0 ± 4.9 245.4 ± 10.4	168	181	215	236	264	286	295
70+	127	224.8 ± 3.0	218.6 ± 4.0 229.3 ± 4.4	172	181	196	226	249	270	280

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Plasma Total Cholesterol (mg/dl)

Visit 2, Random Sample.


The LRC Prevalence Study (North America).



#### Plasma Total Cholesterol (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).



# Table 24. Plasma Triglyceride (mg/dl)

White Males – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(100.0)			100an = 0.2.	5	10	25	50	75	90	95
0-4	20			_	_	_				
5-9	148	51.9 ± 1.7	50.2 ± 3.5 53.2 ± 2.1	28	34	39	48	58	70	85
10-14	299	63.4 ± 1.6	53.9 ± 5.2 67.2 ± 4.5	33	37	46	58	74	94	111
15-19	299	78.2 ± 2.4	74.1 ± 4.3 80.1 ± 4.1	38	43	53	68	88	125	143
20-24	118	89.3 ± 3.7	87.9 ± 5.2 98.5 ± 9.4	44	50	61	78	107	146	165
25-29	253	104.2 ± 4.2	80.2 ± 5.4 125.3 ± 14.1	45	51	67	88	120	171	204
30-34	403	122.1 ± 3.7	$95.4 \pm 4.6$ $148.0 \pm 22.3$	46	57	76	102	142	214	253
35-39	372	140.8 ± 5.5	115.8 ± 12.5 160.8 ± 19.4	52	58	80	109	167	250	316
40-44	385	152.4 ± 6.9	117.5 ± 9.6 197.3 ± 41.6	56	69	89	123	174	252	318
45-49	327	143.4 ± 5.9	124.4 ± 8.7 184.7 ± 34.1	56	65	88	119	165	218	279
50-54	340	153.4 ± 5.5	122.8 ± 9.0 161.4 ± 12.0	63	75	94	128	178	244	313
55-59	261	134.3 ± 4.2	129.8 ± 10.4 146.9 ± 12.1	60	70	85	117	167	210	261
60-64	131	130.6 ± 8.7	125.8 ± 10.1 148.4 ± 30.9	56	65	84	111	150	193	240
65-69	105	138.6 ± 11.1	135.9 ± 16.8 144.8 ± 20.5	54	61	78	108	164	227	256
70+	119	132.8 ± 7.2	130.9 ± 8.9 130.9 ± 8.9	63	71	87	115	152	202	239

Note. Mean not given if N < 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 25. Plasma Triglyceride (mg/dl)

White Females (Total) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

	,			- 1	_				_	
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
				5	10	25	50	75	90	95
0-4	18		_		_					
5-9	126	63.8 ± 2.5	50.6 ± 3.3 69.9 ± 3.5	32	37	45	57	74	103	126
10-14	248	72.0 ± 1.7	65.5 ± 4.5 82.6 ± 7.2	39	44	53	68	85	104	120
15-19	297	72.8 ± 1.9	65.7 ± 5.4 75.8 ± 4.7	36	40	52	64	85	112	126
20-24	199	87.3 ± 2.9	85.6 ± 5.6 93.8 ± 7.8	37	42	60	80	104	135	168
25-29	314	87.4 ± 2.8	$78.9 \pm 5.0$ $103.8 \pm 13.0$	42	45	57	76	104	137	159
30-34	337	86.0 ± 2.8	77.4 ± 6.1 102.3 ± 11.4	40	45	55	73	104	140	163
35-39	300	98.3 ± 3.2	71.0 ± 6.6 118.5 ± 11.7	40	47	61	83	115	170	205
40-44	319	98.1 ± 2.6	85.3 ± 6.1 110.3 ± 7.7	45	51	66	88	116	161	191
45-49	329	112.5 ± 3.4	97.2 ± 11.9 134.7 ± 12.7	44	55	71	94	139	180	223
50-54	257	116.0 ± 3.4	99.0 ± 8.5 131.1 ± 11.6	53	58	75	103	144	190	223
55-59	251	133.1 ± 4.8	123.3 ± 15.6 155.9 ± 10.6	59	65	80	111	163	229	279
60-64	145	132.1 ± 9.1	118.7 ± 6.3 130.4 ± 9.8	57	66	78	105	143	210	256
65-69	130	136.5 ± 6.8	129.3 ± 8.4 163.2 ± 13.0	56	64	86	118	158	221	260
70+	143	128.3 ± 6.5	120.5 ± 8.0 138.5 ± 10.8	60	68	83	110	141	189	289

Note: Mean not given if N < 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50;

50th percentile not given if N < 40.

# Table 26. Plasma Triglyceride (mg/dl)

White Females (Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

				-			-		
AGE N (Years)	OVERALL CLINIC RANGE Mean ± S.E. Mean ± S.E.	CLINIC RANGE			PER	CENT	ILES		
(Tears)	Wicari I O.L.	Weart = O.E.	5	10	25	50	75	90	95
0-4 0		_		_	_	_	_	_	
5-9 0	- 0	_	_	_	_	_	_		_
10-14 0	<u> </u>	<del></del>		_				_	
15-19 20	<del>-</del>	_			_	_	_	_	
20-24 101	105.6 ± 4.0	$105.0 \pm 6.8$ $107.4 \pm 7.0$	54	62	78	99	120	161	175
25-29 132	109.4 ± 5.3	$103.6 \pm 9.0$ $109.2 \pm 7.5$	52	59	75	96	126	161	201
30-34 97	114.6 ± 5.3	_		60	80	104	138	176	
35-39 50	146.3 ± 10.2	<del></del>	_		92	123	177		
40-44 63	123.6 ± 6.1	_	_	_	89	109	157	_	
45-49 72	137.7 ± 8.3	<del>-</del>		_	83	131	165		
50-54 70	127.8 ± 6.4	<del></del>	_		90	114	148	_	
55-59 60	138.2 ± 9.8				91	117	170		
60-64 32	126.0 ± 10.4	_							_
65-69 25	132.6 ± 15.3						_	_	
70+ 10		<del>_</del>		_	_			_	

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 27. Plasma Triglyceride (mg/dl)

White Females (Non-Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE	N	OVERALL	CLINIC RANGE	PERCENTILES								
(Years)		Mean ± S.E.	Mean ± S.E.		10	25	50	75	90	95		
0-4	18	_	_	_	_				_	_		
5-9	126	63.8 ± 2.5	50.6 ± 3.3 69.9 ± 3.5	32	37	45	57	74	103	126		
10-14	248	72.0 ± 1.7	65.5 ± 4.5 82.6 ± 7.2	39	44	53	68	85	104	120		
15-19	276	70.8 ± 1.8	65.4 ± 5.6 75.8 ± 5.0	36	40	52	63	84	108	122		
20-24	96	68.2 ± 3.4	69.3 ± 4.5 69.3 ± 4.5	_	37	45	65	81	100			
25-29	181	71.1 ± 2.2	64.7 ± 4.5 77.3 ± 6.9	40	43	51	64	86	108	130		
30-34	235	74.3 ± 3.1	69.9 ± 4.9 92.7 ± 17.1	38	42	50	63	84	115	140		
35-39	243	87.9 ± 3.0	92.2 ± 7.0 102.6 ± 10.1	38	45	58	77	98	148	175		
40-44	245	90.1 ± 2.7	72.6 ± 4.1 98.4 ± 7.9	44	49	61	80	103	150	165		
45-49	249	103.2 ± 3.5	96.1 ± 8.0 119.9 ± 11.0	44	53	69	90	124	164	188		
50-54	178	108.9 ± 4.0	$97.5 \pm 9.5$ $129.2 \pm 13.3$	52	56	72	95	128	180	212		
55-59	172	130.8 ± 5.9	127.0 ± 10.6 156.4 ± 13.7	59	65	77	107	161	232	269		
60-64	111	134.0 ± 11.5	120.8 ± 7.9 131.3 ± 11.0	57	62	76	103	142	227	263		
65-69	101	138.8 ± 7.9	126.9 ± 9.2 176.8 ± 15.6	56	65	89	119	163	223	262		
70+	127	131.2 ± 7.1	120.8 ± 8.6 145.9 ± 12.1	61	69	85	114	141	193	318		

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Plasma Triglyceride (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).



Figure 43 White Females (Total)





Figure 44 **White Females** 

Figure 45 White Males/White Females (Total)




10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.

# Plasma Triglyceride (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).



#### Table 28. Plasma VLDL-Cholesterol (mg/dl)

White Males - Visit 2, Random Sample.

The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
				5	10	25	50	75	90	95
0-4	9		_		_	_		_	_	
5-9	132	8.2 ± 0.5	7.6 ± 1.6 8.5 ± 0.5	0	2	4	7	11	15	18
10-14	288	9.9 ± 0.4	8.2 ± 1.1 11.4 ± 1.3	1	2	5	9	13	18	22
15-19	297	12.8 ± 0.5	12.6 ± 0.8 14.8 ± 0.8	2	3	8	12	17	23	26
20-24	118	13.7 ± 0.8	13.8 ± 1.2 14.7 ± 1.8	1	5	8	12	18	24	28
25-29	253	17.4 ± 0.9	16.0 ± 1.6 22.1 ± 2.7	3	6	9	15	22	31	36
30-34	403	21.3 ± 0.9	16.4 ± 0.9 27.9 ± 3.7	5	8	11	18	26	36	48
35-39	372	24.1 ± 1.0	$20.5 \pm 2.9$ $30.1 \pm 5.0$	3	7	12	19	30	46	56
40-44	385	25.5 ± 1.2	20.5 ± 2.3 31.0 ± 7.3	5	8	14	21	30	42	56
45-49	326	24.4 ± 1.1	19.3 ± 2.8 32.4 ± 5.4	5	8	13	20	31	40	51
50-54	340	26.8 ± 1.1	22.3 ± 2.7 29.2 ± 2.9	8	10	14	23	33	49	62
55-59	261	21.6 ± 1.1	15.7 ± 2.6 24.8 ± 4.5	3	6	11	19	28	39	49
60-64	131	18.9 ± 1.3	16.6 ± 2.7 22.9 ± 3.7	3	4	9	16	23	35	44
65-69	105	19.7 ± 2.0	16.0 ± 2.6 24.2 ± 4.0	0	3	8	16	23	40	45
70+	119	17.0 ± 1.2	15.9 ± 1.5 15.9 ± 1.5	0	3	7	15	23	31	38

Note: Mean not given if N < 25;
5th and 95th percentiles not given if N < 100;
10th and 90th percentiles not given if N < 75;
25th and 75th percentiles not given if N < 50;
50th percentile not given if N < 40.

#### Table 29. Plasma VLDL-Cholesterol (mg/dl)

White Females (Total) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(16415)		Wear - S.E.	Wearr ± 3.E.	5	10	25	50	75	90	95
0-4	6		_	_						
5-9	113	9.7 ± 0.7	10.7 ± 0.9 10.7 ± 0.9	1	1	4	9	13	19	24
10-14	245	10.9 ± 0.4	9.9 ± 1.5 12.3 ± 2.1	2	3	6	10	15	20	23
15-19	295	11.8 ± 0.5	8.2 ± 1.4 15.1 ± 1.0	2	3	6	11	15	21	24
20-24	199	13.5 ± 0.6	12.1 ± 1.7 15.2 ± 1.1	2	4	8	13	18	24	28
25-29	314	13.4 ± 0.5	11.5 ± 1.4 15.6 ± 1.1	2	3	7	11	19	24	29
30-34	333	12.2 ± 0.5	11.0 ± 1.0 13.8 ± 1.5	1	3	6	11	17	21	27
35-39	299	15.4 ± 0.7	12.2 ± 1.7 20.7 ± 2.9	2	3	8	13	21	29	36
40-44	319	14.7 ± 0.5	9.5 ± 1.5 20.0 ± 2.3	3	5	8	13	20	28	32
45-49	327	17.4 ± 0.7	13.1 ± 1.9 22.5 ± 2.9	2	4	9	15	22	33	41
50-54	256	17.2 ± 0.7	7.9 ± 1.3 20.7 ± 2.6	2	5	9	15	23	32	37
55-59	250	20.7 ± 1.0	17.0 ± 1.9 24.7 ± 2.8	2	4	9	18	28	37	49
60-64	145	16.7 ± 1.8	11.2 ± 1.2 17.0 ± 2.0	1	3	6	13	20	29	39
65-69	130	17.0 ± 1.3	14.5 ± 1.6 23.5 ± 2.5	0	3	7	13	21	36	41
70+	143	15.6 ± 1.2	12.3 ± 1.3 19.6 ± 2.0	0	1	6	13	19	32	48

Note. Mean not given if N · 25;

5th and 95th percentiles not given if N  $\sim$  100; 10th and 90th percentiles not given if N  $\sim$  75; 25th and 75th percentiles not given if N  $\sim$  50; 50th percentile not given if N  $\sim$  40.

#### Table 30. Plasma VLDL-Cholesterol (mg/dl)

White Females (Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(Years)		Mean ± 5.E.	Mean ± 5.E.	5	10	25	50	75	90	95
0-4	0	<del></del>			_	_		_	_	_
5-9	0	<del></del>		_		_	_	_	_	_
10-14	0	<del></del>	<del></del>	_	_	_	_	_	_	_
15-19	20	<del></del>	<del></del>	_					_	_
20-24	101	15.2 ± 0.9	15.6 ± 1.6 16.5 ± 1.7	1	4	9	14	19	27	30
25-29	132	15.3 ± 1.0	16.7 ± 1.8 18.4 ± 1.5	2	3	6	13	20	28	36
30-34	95	15.6 ± 0.9	<u> </u>	_	5	9	15	19	24	_
35-39	50	20.4 ± 2.0	<del>-</del>			10	15	26	_	_
40-44	63	17.2 ± 1.5	_	_	_	7	16	23	_	_
45-49	72	19.0 ± 1.4	<del></del>	-		11	17	24	_	_
50-54	70	18.7 ± 1.1	<del></del>	_	_	11	18	26	_	
55-59	60	19.2 ± 1.9	<u> </u>	_		7	17	25	_	_
60-64	32	13.5 ± 1.3					_	_	_	
65-69	25	15.6 ± 2.7	<u> </u>	_	_		_	<u> </u>	_	
70+	10		_					-	-	_

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 31. Plasma VLDL-Cholesterol (mg/dl)

White Females (Non-Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

405	N	OVERALL	OLINIO BANOE			050	OENT		_	
AGE (Years)	IN	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
,				5	10	25	50	75	90	95
0-4	6		and the same of th	www.	warene	MANAGEMENT.		********	_	_
5-9	113	9.7 ± 0.7	10.7 ± 0.9 10.7 ± 0.9	1	1	4	9	13	19	24
10-14	245	10.9 ± 0.4	9.9 ± 1.5 12.3 ± 2.1	2	3	6	10	15	20	23
15-19	274	11.7 ± 0.5	10.8 ± 1.2 14.9 ± 1.1	2	4	6	11	15	21	24
20-24	96	11.9 ± 0.7	10.9 ± 1.1 10.9 ± 1.1		3	7	10	16	22	
25-29	181	12.0 ± 0.6	12.2 ± 1.5 13.1 ± 1.5	2	4	6	11	17	22	24
30-34	233	10.8 ± 0.6	10.2 ± 1.4 11.9 ± 1.5	0	2	5	9	15	20	25
35-39	242	14.3 ± 0.7	13.9 ± 2.0 18.5 ± 3.0	1	3	7	13	19	26	35
40-44	245	13.9 ± 0.5	11.6 ± 1.2 15.1 ± 1.4	3	5	8	12	19	26	29
45-49	247	16.8 ± 0.8	15.7 ± 1.7 20.5 ± 2.6	2	4	9	14	21	32	38
50-54	177	16.4 ± 0.9	17.1 ± 2.3 20.8 ± 3.2	0	4	8	14	22	32	37
55-59	172	21.2 ± 1.3	20.2 ± 2.7 24.7 ± 2.5	2	4	9	18	28	40	51
60-64	111	17.6 ± 2.3	11.6 ± 1.6 17.5 ± 2.3	1	3	6	13	20	30	45
65-69	101	17.6 ± 1.6	14.5 ± 1.8 25.6 ± 3.0	0	3	7	15	22	36	40
70+	127	16.2 ± 1.3	12.7 ± 1.4 20.8 ± 2.2	0	0	7	13	20	34	52

Note: Mean not given if N < 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 50.

#### Plasma VLDL-Cholesterol (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).



Means and Selected Percentiles.




Figure 51 White Females (Total)

Means and Selected Percentiles.




Figure 52 White Females

Comparison of Medians by Sex Hormone Usage.





Figure 53
White Males/White Females (Total)

Comparison of Medians.




Note: Mean not given if N < 25; 10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.

#### Plasma VLDL-Cholesterol (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).



#### Table 32. Plasma LDL-Cholesterol (mg/dl)

White Males - Visit 2, Random Sample.

The LRC Prevalence Study (North America).

		6								
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
				5	10	25	50	75	90	95
0-4	9	- Administration						_		
5-9	132	92.5 ± 1.8	90.9 ± 3.9 92.9 ± 2.1	63	69	80	90	103	117	129
10-14	288	96.8 ± 1.4	84.8 ± 3.0 101.5 ± 3.8	64	73	82	94	109	123	133
15-19	298	94.4 ± 1.3	92.5 ± 3.4 95.5 ± 2.3	62	68	80	93	109	123	130
20-24	118	103.3 ± 2.4	101.6 ± 3.0 108.4 ± 5.2	66	73	85	101	118	138	147
25-29	253	116.7 ± 1.9	109.6 ± 3.5 120.6 ± 4.7	70	75	96	116	138	157	165
30-34	403	126.4 ± 1.6	119.8 ± 4.4 128.7 ± 5.7	78	88	107	124	144	166	185
35-39	372	133.2 ± 1.7	118.4 ± 3.9 145.6 ± 5.7	81	92	110	131	154	176	189
40-44	385	135.6 ± 1.6	129.5 ± 4.3 146.1 ± 4.5	87	98	115	135	157	173	186
45-49	326	143.7 ± 1.8	132.9 ± 3.6 155.8 ± 6.6	97	106	120	140	163	185	202
50-54	340	142.3 ± 1.7	137.0 ± 4.2 154.1 ± 4.2	89	102	118	143	162	185	197
55-59	261	145.8 ± 2.1	137.0 ± 5.6 160.5 ± 5.9	88	103	123	145	168	191	203
60-64	131	146.3 ± 3.1	148.2 ± 5.1 157.3 ± 7.2	83	106	121	143	165	188	210
65-69	105	150.4 ± 3.5	146.3 ± 5.5 153.4 ± 5.0	98	104	125	146	170	199	210
70+	119	142.9 ± 2.9	141.5 ± 3.5 141.5 ± 3.5	88	100	119	142	164	182	186

Note: Mean not given if N < 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 33. Plasma LDL-Cholesterol (mg/dl)

White Females (Total) - Visit 2, Random Sample. The LRC Prevalence Study (North America).

										0
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
				5	10	25	50	75	90	95
0-4	5	_	_	_	_				_	_
5-9	114	100.4 ± 2.1	100.0 ± 2.1 100.0 ± 2.1	68	73	88	98	115	125	140
10-14	245	97.4 ± 1.3	96.4 ± 4.4 97.1 ± 1.6	68	73	81	94	110	126	136
15-19	295	95.7 ± 1.5	93.0 ± 5.4 95.3 ± 4.1	59	66	78	93	110	129	137
20-24	199	103.7 ± 2.2	97.1 ± 3.6 109.4 ± 4.9	57	65	82	102	118	141	159
25-29	314	110.2 ± 1.6	106.6 ± 3.2 120.3 ± 4.6	71	75	90	108	126	148	164
30-34	333	111.3 ± 1.5	107.9 ± 4.3 120.6 ± 4.9	70	77	91	109	129	146	156
35-39	299	119.7 ± 2.0	106.5 ± 5.2 130.3 ± 6.1	75	81	96	116	139	161	172
40-44	319	125.1 ± 1.8	114.4 ± 6.7 131.4 ± 5.8	74	84	104	122	146	165	174
45-49	327	129.4 ± 1.9	123.2 ± 5.6 135.1 ± 3.7	79	89	105	127	150	173	186
50-54	256	138.1 ± 2.3	131.2 ± 5.5 145.0 ± 7.1	88	94	111	134	160	186	201
55-59	250	146.1 ± 2.4	135.9 ± 5.4 157.7 ± 6.0	89	97	120	145	168	199	210
60-64	145	152.0 ± 3.6	153.9 ± 5.6 155.4 ± 6.7	100	105	126	149	168	191	224
65-69	130	153.8 ± 4.1	152.6 ± 4.5 161.1 ± 9.2	92	99	125	151	184	205	221
70+	143	148.6 ± 2.7	146.9 ± 3.7 150.0 ± 3.8	96	108	127	147	170	189	206

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N · 75; 25th and 75th percentiles not given if N · 50; 50th percentile and given if N · 60; 50th percentile not given if N < 40.

#### Table 34. Plasma LDL-Cholesterol (mg/dl)

White Females (Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(Tears)		Wear ± O.L.	Wearr ± G.E.	5	10	25	50	75	90	95
0-4	0	<del></del>	<del></del>	-	_		_			
5-9	0	<del></del>	<del></del>	-	_					_
10-14	0	<del></del>	<del></del>		_	_	_	_	_	_
15-19	20		<del>_</del>	_	_					
20-24	101	108.3 ± 3.3	102.3 ± 5.1 102.7 ± 5.4	62	66	86	106	124	149	163
25-29	132	115.9 ± 2.5	110.5 ± 4.9 112.6 ± 5.8	72	80	97	111	133	157	169
30-34	95	117.4 ± 3.1	<del>_</del>	<b> </b>	80	98	110	134	155	
35-39	50	118.9 ± 5.4	<del>_</del>	-	_	97	114	137		
40-44	63	124.8 ± 4.7			_	94	124	157	_	_
45-49	72	127.5 ± 4.0	<del>-</del>	1		102	127	150	_	_
50-54	70	119.7 ± 3.3	<del></del>	_	_	98	120	135	_	
55-59	60	132.5 ± 4.7	_			104	129	156		_
60-64	32	136.6 ± 5.0	_	_	_		_	_	_	_
65-69	25	126.4 ± 5.7					_			
70+	10	_	_	_		_	_	_		

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 35. Plasma LDL-Cholesterol (mg/dl)

White Females (Non-Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE	N	OVERALL	CLINIC RANGE			PER	CENT	ILES		
(Years)		Mean ± S.E.	Mean ± S.E.	5	10	25	50	75	90	95
0-4	5		<u> </u>	_	_	_				_
5-9	114	100.4 ± 2.1	100.0 ± 2.1 100.0 ± 2.1	68	73	88	98	115	125	140
10-14	245	97.4 ± 1.3	96.4 ± 4.4 97.1 ± 1.6	68	73	81	94	110	126	136
15-19	274	94.9 ± 1.4	93.5 ± 2.1 96.9 ± 4.1	60	67	78	93	110	127	135
20-24	96	98.1 ± 2.8	$99.3 \pm 5.0$ $99.3 \pm 5.0$		62	80	98	113	136	_
25-29	181	106.0 ± 2.0	101.8 ± 5.2 108.0 ± 4.7	70	73	87	103	122	141	151
30-34	233	109.0 ± 1.7	$103.1 \pm 4.3$ $118.5 \pm 6.4$	67	76	89	109	127	142	150
35-39	242	118.8 ± 2.1	119.7 ± 4.6 126.1 ± 5.6	76	81	96	116	139	161	172
40-44	245	125.2 ± 2.0	116.2 ± 5.5 133.0 ± 7.9	77	89	105	120	146	164	174
45-49	247	129.7 ± 2.1	122.4 ± 7.3 134.9 ± 5.5	80	90	105	127	150	173	187
50-54	177	146.1 ± 2.9	145.1 ± 7.2 155.4 ± 8.8	90	102	118	141	169	192	215
55-59	172	151.8 ± 2.9	151.9 ± 8.4 158.5 ± 6.4	95	103	126	148	176	204	213
60-64	111	156.3 ± 4.5	155.0 ± 6.6 165.3 ± 8.7	100	105	130	151	172	201	234
65-69	101	161.6 ± 4.7	160.1 ± 5.2 171.8 ± 10.3	97	104	128	156	189	208	223
70+	127	148.9 ± 2.9	145.5 ± 4.2 151.5 ± 4.1	96	107	126	146	170	189	207


Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Plasma LDL-Cholesterol (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).

10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.



74

#### Plasma LDL-Cholesterol (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).




Table 36. Plasma HDL-Cholesterol (mg/dl)

White Males - Visit 2, Random Sample.

The LRC Prevelance Study (North America).

AGE	N	OVERALL Magn + S.F.	CLINIC RANGE			PER	CENT	ILES		
(Years)		Mean ± S.E.	Mean ± S.E.	5	10	25	50	75	90	95
0-4	17	<del></del> -	_							
5-9	145	55.8 ± 1.0	54.8 ± 1.8 56.0 ± 1.1	38	43	49	55	63	70	75
10-14	298	54.9 ± 0.7	53.9 ± 1.0 58.5 ± 2.3	37	40	46	55	61	71	74
15-19	300	46.1 ± 0.6	42.2 ± 1.2 48.6 ± 1.6	30	34	39	46	52	59	63
20-24	118	45.4 ± 1.0	40.0 ± 1.6 48.2 ± 1.8	30	32	38	45	51	57	63
25-29	253	44.7 ± 0.7	39.6 ± 1.8 45.7 ± 1.2	31	32	37	44	50	58	63
30-34	403	45.5 ± 0.6	$39.8 \pm 1.6$ $50.2 \pm 2.2$	28	32	38	45	52	59	63
35-39	372	43.5 ± 0.6	34.6 ± 1.2 48.0 ± 1.8	29	31	36	43	49	58	62
40-44	385	44.2 ± 0.6	35.5 ± 1.7 49.9 ± 2.1	27	31	36	43	51	60	67
45-49	326	45.5 ± 0.6	40.2 ± 2.0 49.3 ± 2.2	30	33	38	45	52	60	64
50-54	340	44.1 ± 0.6	36.5 ± 1.3 50.1 ± 2.1	28	31	36	44	51	58	63
55-59	261	47.6 ± 0.9	41.2 ± 1.6 51.1 ± 3.0	28	31	38	46	55	64	71
60-64	131	51.5 ± 1.3	44.8 ± 2.2 54.6 ± 2.3	30-	34	41	49	61	69	74
65-69	105	51.1 ± 1.5	41.2 ± 2.1 56.7 ± 2.1	30	33	39	49	62	74	78
70+	119	50.5 ± 1.7	53.2 ± 2.1 53.2 ± 2.1	31	33	40	48	56	70	75

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 37. Plasma HDL-Cholesterol (mg/dl)

White Females (Total) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE	N	OVERALL	CLINIC RANGE			PER	CENT	ILES		
(Years)		Mean ± S.E.	Mean ± S.E.	5	10	25	50	75	90	95
0-4	15	_				_				
5-9	127	53.2 ± 1.0	51.5 ± 1.1 56.5 ± 2.7	36	38	48	52	60	67	73
10-14	248	52.2 ± 0.7	$51.3 \pm 0.8$ $53.0 \pm 1.8$	37	40	45	52	58	64	70
15-19	297	52.3 ± 0.7	50.2 ± 1.3 53.7 ± 3.1	35	38	43	51	61	68	74
20-24	199	53.3 ± 1.0	43.6 ± 2.2 56.9 ± 1.9	33	37	44	51	62	72	79
25-29	314	56.0 ± 0.8	46.9 ± 1.8 60.4 ± 1.9	37	39	47	55	63	74	83
30-34	336	56.0 ± 0.7	48.5 ± 1.8 62.7 ± 2.2	36	40	46	55	64	73	77
35-39	299	55.0 ± 0.8	45.5 ± 1.6 61.7 ± 2.6	34	38	44	53	64	75	82
40-44	319	57.8 ± 0.9	47.4 ± 2.6 64.0 ± 3.5	34	39	48	56	65	79	88
45-49	329	59.4 ± 1.0	47.3 ± 2.6 66.5 ± 3.4	34	41	47	58	68	82	87
50-54	256	62.0 ± 1.0	57.0 ± 2.7 75.6 ± 3.0	37	41	50	62	71	84	92
55-59	250	62.2 ± 1.1	55.3 ± 2.0 67.4 ± 3.6	37	41	50	60	73	85	91
60-64	145	63.8 ± 1.4	54.6 ± 2.1 68.2 ± 2.0	38	44	51	61	75	87	92
65-69	130	63.3 ± 1.8	50.3 ± 2.2 68.6 ± 2.2	35	38	49	62	73	85	98
70+	143	60.7 ± 1.4	53.3 ± 1.9 66.6 ± 1.9	33	38	48	60	71	82	92

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

## Table 38. Plasma HDL-Cholesterol (mg/dl)

White Females (Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
(10010)		1710d11 = 0.1E.	WIGGIT = 0.2.	5	10	25	50	75	90	95
0-4	0				_	_	_	_	_	_
5-9	0			_		_	_	_	_	_
10-14	0	<del></del>			, <u></u>	<del></del>		_		
15-19	20	Y —	_				-	_	_	_
20-24	101	54.7 ± 1.4	55.5 ± 3.1 59.4 ± 2.1	34	38	44	53	64	74	79
25-29	132	56.1 ± 1.3	53.5 ± 2.2 57.9 ± 2.6	35	38	47	54	62	75	83
30-34	97	58.0 ± 1.7	_	_	36	47	57	69	77	_
35-39	50	57.0 ± 2.2	<del>_</del>	_	_	47	57	68	_	_
40-44	63	61.1 ± 2.5				49	57	69		
45-49	72	65.5 ± 2.1	<del></del>	_	_	52	64	<b>7</b> 7	_	
50-54	70	67.6 ± 2.1				54	68	77	_	-
55-59	60	70.8 ± 2.3	_	_	_	60	71	82		
60-64	32	70.4 ± 2.8	_	_	_		_	_	_	_
65-69	25	76.1 ± 4.7				_	-	_	_	_
70+	10		-			_	_		_	_

Note. Mean not given it N - 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 39. Plasma HDL-Cholesterol (mg/dl)

White Females (Non-Sex Hormone Users) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

			7.	vortii America).	v		, .				
AGE (Years)	N	OVERALL Mean ± S.E.		CLINIC RANGE Mean ± S.E.			PER	CENT	ILES		
					5	10	25	50	75	90	95
0-4	15										*******
5-9	127	53.2 ± 1.0		51.5 ± 1.1 56.5 ± 2.7	36	38	48	52	60	67	73
10-14	248	52.2 ± 0.7		51.3 ± 0.8 53.0 ± 1.8	37	40	45	52	58	64	70
15-19	276	52.0 ± 0.7		49.7 ± 1.3 53.4 ± 3.2	35	38	43	51	61	68	73
20-24	96	52.2 ± 1.5	l	54.6 ± 3.0 54.6 ± 3.0		37	43	50	60	68	_
25-29	181	56.0 ± 1.0		49.6 ± 2.2 58.4 ± 2.6	37	40	47	55	64	73	81
30-34	234	55.4 ± 0.8		47.4 ± 1.4 57.1 ± 2.0	38	40	46	55	64	71	75
35-39	242	54.8 ± 0.9		46.2 ± 1.6 55.1 ± 1.9	34	38	44	52	63	75	82
40-44	245	57.1 ± 1.0		50.2 ± 2.9 61.2 ± 2.6	33	39	48	56	64	78	87
45-49	249	57.7 ± 1.1		52.2 ± 2.3 64.6 ± 4.0	33	39	46	56	66	78	86
50-54	177	60.1 ± 1.1		54.6 ± 2.9 61.3 ± 3.1	37	40	49	59	70	77	89
55-59	172	59.1 ± 1.3		49.5 ± 2.9 61.5 ± 3.1	36	39	47	58	68	82	86
60-64	111	62.0 ± 1.6		53.9 ± 2.3 65.8 ± 2.4	36	43	49	60	73	85	91
65-69	101	60.5 ± 1.8		48.0 ± 2.4 65.5 ± 2.3	34	38	46	60	71	79	89
70+	127	60.1 ± 1.5		52.4 ± 2.1 65.8 ± 2.0	33	37	48	60	69	82	91

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Plasma HDL-Cholesterol (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).



Means and Selected Percentiles.

#### Figure 67 White Females (Total)

Means and Selected Percentiles.




Figure 68 **White Females** 

Comparison of Medians by Sex Hormone Usage.

Figure 69 White Males/White Females (Total) Comparison of Medians.




Note: Mean not given if N < 25;

10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.


#### Plasma HDL-Cholesterol (mg/dl)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).







Blood Pressure (mm Hg) by Age and Sex. Means and Selected Percentiles.

Visit 2, Random Sample, Whites.

A. Standard
Sphygmomanometer
Measurements

# Table 40. Systolic Blood Pressure Measurements (mm Hg) by Standard Sphygmomanometer

White Males - Visit 2, Random Sample.

AGE	N	OVERALL	CLINIC RANGE		PEF	RCENTII	_ES	
(Years)		Mean ± S.E.	Mean ± S.E.	10	25	50	75	90
0-4	10			<del></del>				
5-9	112	96.0 ± 0.9	94.3 ± 1.1 101.9 ± 1.5	84	90	95	101	109
10-14	231	102.9 ± 0.7	$98.0 \pm 2.3$ $102.5 \pm 0.9$	90	95	102	110	117
15-19	254	114.2 ± 0.7	113.8 ± 1.7 114.6 ± 1.1	100	108	115	121	128
20-24	111	121.9 ± 1.2	118.3 ± 1.3 126.7 ± 2.1	107	112	122	128	136
25-29	246	118.8 ± 0.8	115.3 ± 1.5 122.5 ± 1.9	104	111	118	125	135
30-34	377	120.3 ± 0.6	115.9 ± 1.3 130.4 ± 3.0	105	112	120	128	136
35-39	340	119.0 ± 0.7	116.2 ± 1.4 122.4 ± 2.1	105	111	118	127	135
40-44	362	121.5 ± 0.7	118.8 ± 1.7 124.2 ± 2.0	107	113	120	128	138
45-49	300	121.6 ± 0.9	117.8 ± 2.6 125.0 ± 2.1	104	111	120	130	142
50-54	319	127.3 ± 1.1	124.5 ± 3.3 128.8 ± 2.7	106	115	125	135	152
55-59	245	130.4 ± 1.1	128.4 ± 2.9 133.2 ± 2.9	109	118	129	141	150
60-64	103	136.2 ± 1.7	129.9 ± 2.6 137.0 ± 3.4	115	124	. 136	146	157
65-69	80	143.4 ± 2.1	142.5 ± 3.5 144.9 ± 3.4	120	130	141	156	170
70+	65	145.9 ± 2.4	145.1 ± 3.3 145.1 ± 3.3		132	144	159	

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Table 41. Systolic Blood Pressure Measurements (mm Hg) by Standard Sphygmomanometer

White Females - Visit 2, Random Sample.

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PEF	RCENTI	LES	
				10	25	50	75	90
0-4	14		_			_	******	
5-9	90	98.3 ± 1.2	96.0 ± 1.3 96.0 ± 1.3	87	90	98	103	112
10-14	187	103.7 ± 0.8	101.9 ± 1.6 104.4 ± 1.0	91	95	101	111	119
15-19	238	107.7 ± 0.7	105.5 ± 1.1 109.4 ± 1.3	95	101	107	114	121
20-24	191	109.4 ± 0.7	$107.3 \pm 1.7$ $113.4 \pm 2.3$	96	103	109	115	123
25-29	293	110.4 ± 0.7	106.8 ± 1.9 112.1 ± 1.4	97	102	108	117	126
30-34	292	109.7 ± 0.6	105.6 ± 1.8 111.9 ± 1.5	97	102	110	116	124
35-39	266	113.0 ± 0.9	109.4 ± 2.2 116.9 ± 3.0	98	103	111	121	128
40-44	282	115.4 ± 0.9	113.7 ± 2.4 117.2 ± 2.2	100	105	113	122	133
45-49	308	118.0 ± 0.9	111.8 ± 2.3 121.2 ± 2.4	100	107	116	127	138
50-54	230	125.2 ± 1.2	118.6 ± 3.2 127.4 ± 3.6	101	112	123	136	151
55-59	229	130.5 ± 1.3	126.1 ± 3.0 133.5 ± 2.4	107	116	129	138	158
60-64	114	138.1 ± 2.0	134.1 ± 4.1 142.8 ± 3.3	111	121	136	151	165
65-69	83	143.2 ± 2.5	142.2 ± 4.9 146.7 ± 2.9	114	128	145	153	162
70+	99	143.3 ± 2.3	140.5 ± 3.7 145.3 ± 2.9	120	124	140	160	173

Note: Mean not given if N < 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Systolic Blood Pressure Measurements (mm Hg) by Standard Sphygmomanometer.

Visit 2, Random Sample.






Figure 76
White Males/White Females (Total)





Note: Mean not given if N < 25; 10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.

# Table 42. Diastolic Blood Pressure Measurements (mm Hg) by Standard Sphygmomanometer

White Males - Visit 2, Random Sample.

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PER	CENTI	LES	
				10	25	50	75	90
0-4	10							
5-9	112	58.9 ± 1.1	56.1 ± 1.3 66.6 ± 1.8	41	51	60	67	71
10-14	229	63.7 ± 0.7	62.4 ± 0.9 64.3 ± 1.4	50	58	64	70	77
15-19	254	68.8 ± 0.6	67.5 ± 1.0 70.4 ± 1.5	56	62	70	76	81
20-24	111	74.9 ± 1.0	76.0 ± 1.3 77.4 ± 1.5	60	69	76	80	85
25-29	246	75.8 ± 0.6	71.1 ± 1.3 78.8 ± 1.2	64	69	76	81	89
30-34	377	77.5 ± 0.5	72.7 ± 1.1 85.6 ± 1.5	67	70	78	84	89
35-39	340	78.0 ± 0.5	74.4 ± 1.1 81.5 ± 1.8	67	71	77	84	91
40-44	362	80.0 ± 0.5	75.7 ± 1.3 81.8 ± 2.0	69	73	80	86	93
45-49	300	80.9 ± 0.6	78.1 ± 1.2 83.7 ± 1.7	68	74	80	87	95
50-54	318	82.5 ± 0.6	79.3 ± 1.7 84.5 ± 1.5	70	76	81	89	97
55-59	245	82.1 ± 0.7	78.0 ± 1.3 85.1 ± 1.5	70	75	81	89	96
60-64	103	84.1 ± 1.1	82.5 ± 1.9 86.7 ± 1.9	72	79	84	90	97
65-69	80	85.9 ± 1.1	85.0 ± 1.7 87.4 ± 1.9	73	79	84	91	99
70+	65	83.6 ± 1.4	83.7 ± 1.8 83.7 ± 1.8		75	82	90	

The LRC Prevalence Study (North America).

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Table 43. Diastolic Blood Pressure Measurements (mm Hg) by Standard Sphygmomanometer

White Females - Visit 2, Random Sample.


AGE N	OVERALL	CLINIC RANGE		DCI	RCENTI	LEC	
(Years)	Mean ± S.E.	Mean ± S.E.		FER	TOENTI	LES	
			10	25	50	75	90
0-4 14	· · · · · · · · · · · · · · · · · · ·	especialis.					
5-9 90	59.0 ± 1.2	55.6 ± 1.5 55.6 ± 1.5	43	50	60	69	73
10-14 186	62.7 ± 0.8	61.4 ± 1.1 67.0 ± 1.2	50	56	63	70	75
15-19 237	67.2 ± 0.6	65.7 ± 0.9 69.6 ± 1.2	57	61	68	73	78
20-24 191	68.0 ± 0.7	64.2 ± 1.4 72.3 ± 1.8	56	61	68	73	80
25-29 293	71.0 ± 0.6	66.1 ± 1.8 73.3 ± 2.0	59	65	71	77	81
30-34 292	71.6 ± 0.5	68.1 ± 1.9 76.8 ± 1.9	60	65	71	79	82
35-39 266	74.8 ± 0.6	69.5 ± 1.4 78.1 ± 2.1	64	68	73	80	87
40-44 282	75.4 ± 0.6	73.9 ± 1.6 77.1 ± 1.5	64	69	74	81	89
45-49 308	76.4 ± 0.6	71.9 ± 1.4 80.5 ± 1.6	63	70	76	83	89
50-54 230	78.7 ± 0.6	76.6 ± 1.6 80.8 ± 2.3	67	72	79	84	91
55-59 229	79.8 ± 0.7	77.4 ± 1.9 82.3 ± 1.4	67	73	80	86	94
60-64 114	82.6 ± 1.1	81.4 ± 1.9 83.1 ± 1.9	69	74	81	90	98
65-69 83	81.5 ± 1.1	82.2 ± 1.9 82.7 ± 1.5	68	74	81	88	91
70+ 99	79.5 ± 1.0	78.8 ± 1.2 80.9 ± 1.6	68	73	80	83	91

The LRC Prevalence Study (North America).

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Diastolic Blood Pressure Measurements (mm Hg) by Standard Sphygmomanometer.

Visit 2, Random Sample.



70+ Age 10

30

40

70+

60

20

Figure 79
White Males / White Females (Total)


40

50

60


10

Age



Note: Mean not given if N < 25; 10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.





Blood Pressure (mm Hg) by Age and Sex. Means and Selected Percentiles.

Visit 2, Random Sample, Whites.

B. Random-Zero Sphygmomanometer Measurements

# Table 44. Systolic Blood Pressure Measurements (mm Hg) by Random-Zero Sphygmomanometer

White Males - Visit 2, Random Sample.

AGE N (Years)	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PEF	RCENTII	LES	
(10010)	Wicarr = O.E.	Wicarr = O.E.	10	25	50	75	90
0-4 10	<del></del>						
5-9 112	94.0 ± 1.1	92.0 ± 1.4 101.7 ± 1.5	79	86	94	102	109
10-14 230	101.1 ± 0.8	97.3 ± 2.2 100.5 ± 1.6	87	93	100	108	117
15-19 253	112.0 ± 0.8	111.2 ± 1.4 112.7 ± 1.8	96	105	111	119	129
20-24 111	120.1 ± 1.1	116.1 ± 1.3 124.1 ± 2.2	106	112	119	127	137
25-29 246	117.3 ± 0.8	114.0 ± 1.5 121.7 ± 2.2	102	109	115	123	134
30-34 376	118.5 ± 0.6	114.7 ± 1.3 128.7 ± 2.6	103	110	118	126	133
35-39 340	116.9 ± 0.7	115.4 ± 1.3 119.0 ± 1.4	103	109	116	125	133
40-44 360	119.8 ± 0.7	116.5 ± 2.2 121.7 ± 2.2	104	111	118	127	137
45-49 299	119.6 ± 0.8	113.1 ± 2.3 124.0 ± 1.9	103	110	118	128	138
50-54 319	125.3 ± 1.0	122.5 ± 2.6 127.1 ± 2.6	105	114	122	134	147
55-59 245	129.1 ± 1.1	125.8 ± 2.7 132.1 ± 3.1	107	118	127	140	151
60-64 103	134.5 ± 1.6	$129.5 \pm 2.7$ $133.6 \pm 3.0$	112	123	134	144	155
65-69 79	141.4 ± 2.1	140.0 ± 3.2 142.9 ± 3.6	119	127	139	153	164
70+ 65	144.3 ± 2.5	144.0 ± 3.3 144.0 ± 3.3		131	145	160	

The LRC Prevalence Study (North America).

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75;

25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Table 45. Systolic Blood Pressure Measurements (mm Hg) by Random-Zero Sphygmomanometer

White Females - Visit 2, Random Sample.

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PER	CENTI	_ES	
(Tears)		Mean - S.L.	Mean ± 3.E.	10	25	50	75	90
0-4	14			************				
5-9	90	97.1 ± 1.2	94.9 ± 1.4 94.9 ± 1.4	83	91	96	104	110
10-14	187	101.3 ± 0.9	100.3 ± 1.8 101.7 ± 1.1	87	93	101	109	116
15-19	232	105.4 ± 0.8	101.4 ± 1.3 108.2 ± 1.5	91	99	105	113	121
20-24	191	107.6 ± 0.8	104.1 ± 1.7 110.2 ± 2.4	95	100	106	114	121
25-29	292	108.3 ± 0.7	105.4 ± 1.8 110.2 ± 1.4	95	100	107	115	122
30-34	292	108.0 ± 0.6	104.5 ± 1.8 111.0 ± 1.6	96	101	108	113	122
35-39	263	111.1 ± 0.9	107.4 ± 2.0 115.3 ± 3.1	96	102	109	119	128
40-44	281	113.5 ± 0.9	112.7 ± 2.5 114.8 ± 2.5	97	104	112	120	130
45-49	308	115.9 ± 0.9	110.7 ± 2.1 120.0 ± 2.5	98	105	113	125	136
50-54	228	123.9 ± 1.3	115.5 ± 2.9 126.6 ± 4.0	101	110	121	135	149
55-59	228	128.8 ± 1.4	125.4 ± 3.0 132.3 ± 2.6	106	115	127	139	157
60-64	114	135.7 ± 2.0	129.8 ± 3.8 141.8 ± 3.1	110	120	134	149	160
65-69	83	142.6 ± 2.5	140.9 ± 4.7 146.9 ± 3.0	115	126	147	153	162
70+	99	144.0 ± 2.3	138.7 ± 3.3 147.5 ± 3.0	116	126	141	160	173

The LRC Prevalence Study (North America).

Note. Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Systolic Blood Pressure Measurements (mm Hg) by Random-Zero Sphygmomanometer.

Visit 2, Random Sample.





Figure 82
White Males/White Females (Total)



ote: Mean not given if N < 25; 10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.

# Table 46. Diastolic Blood Pressure Measurements (mm Hg) by Random-Zero Sphygmomanometer

White Males - Visit 2, Random Sample.

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PEF	CENTIL	ES	
(Tears)		Wear - S.L.	Wearr ± 3.L.	10	25	50	75	90
0-4	10	_				_	_	_
5-9	112	57.6 ± 1.6	54.8 ± 2.2 67.1 ± 1.8	38	47	58	68	73
10-14	230	62.4 ± 0.7	59.0 ± 2.6 63.0 ± 1.4	47	56	62	70	75
15-19	253	68.7 ± 0.6	67.5 ± 1.1 69.1 ± 1.4	55	62	69	76	81
20-24	111	74.1 ± 0.9	74.6 ± 1.1 76.5 ± 1.3	62	68	75	80	86
25-29	246	74.5 ± 0.6	70.8 ± 1.2 78.0 ± 1.8	62	68	74	80	87
30-34	376	76.4 ± 0.5	72.7 ± 1.1 86.4 ± 1.7	65	70	76	83	90
35-39	340	77.1 ± 0.6	74.7 ± 1.1 78.9 ± 2.4	65	71	77	84	90
40-44	359	79.3 ± 0.5	75.3 ± 1.2 82.0 ± 1.9	68	72	79	85	92
45-49	299	79.6 ± 0.6	75.7 ± 1.6 82.1 ± 1.9	67	72	79	86	93
50-54	318	81.4 ± 0.6	78.3 ± 1.7 83.2 ± 1.6	69	75	80	88	95
55-59	245	81.0 ± 0.6	79.6 ± 1.9 81.8 ± 1.3	68	74	81	87	94
60-64	103	81.7 ± 1.2	79.8 ± 1.7 81.9 ± 2.2	66	75	81	88	97
65-69	79	84.0 ± 1.3	82.8 ± 2.4 86.0 ± 1.8	71	77	82	91	99
70+	65	81.7 ± 1.4	82.4 ± 2.0 82.4 ± 2.0		74	81	89	_

The LRC Prevalence Study (North America).

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Table 47. Diastolic Blood Pressure Measurements (mm Hg) by Random-Zero Sphygmomanometer

White Females - Visit 2, Random Sample.

								-
AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.	wtronger de territorie de la constante de la c	PEF	RCENTII	LES	
				10	25	50	75	90
0-4	14							
5-9	90	57.9 ± 1.5	55.0 ± 1.9 55.0 ± 1.9	39	50	60	68	73
10-14	187	61.9 ± 0.9	61.1 ± 1.1 65.0 ± 1.4	48	56	61	70	75
15-19	233	67.7 ± 0.6	65.4 ± 1.1 68.8 ± 1.0	55	61	68	75	79
20-24	191	67.1 ± 0.7	63.0 ± 1.7 71.6 ± 2.2	55	61	67	74	78
25-29	292	69.6 ± 0.6	67.3 ± 1.9 72.0 ± 1.6	58	62	69	76	82
30-34	292	70.1 ± 0.5	66.1 ± 1.6 75.3 ± 1.9	58	64	70	77	81
35-39	263	$73.3 \pm 0.6$	70.1 ± 1.4 76.6 ± 1.9	62	67	72	79	86
40-44	281	74.3 ± 0.6	73.3 ± 1.3 75.8 ± 2.1	62	67	74	80	88
45-49	308	75.3 ± 0.6	73.1 ± 1.5 80.1 ± 1.6	63	68	75	82	89
50-54	228	77.3 ± 0.7	$73.6 \pm 1.8$ $78.0 \pm 2.2$	65	70	77	83	90
55-59	228	78.3 ± 0.7	77.6 ± 1.7 79.4 ± 1.5	64	71	78	84	94
60-64	114	80.0 ± 1.1	79.9 ± 2.1 80.3 ± 1.9	66	72	80	86	93
65-69	83	81.0 ± 1.2	81.6 ± 2.0 82.3 ± 1.8	65	74	81	89	93
70+	99	77.1 ± 1.0	75.6 ± 1.2 79.9 ± 1.7	66	70	77	82	90

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100;

10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Diastolic Blood Pressure Measurements (mm Hg) by Random-Zero Sphygmomanometer.

Visit 2, Random Sample.






Figure 85 White Males/White Females (Total)



Note: Mean not given if N < 25; 10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.






Systolic and Diastolic Blood Pressure (mm Hg) by Age and Sex. Medians.

Visit 2, Random Sample, Whites.

C. Comparison of Standard and Random-Zero Sphygmomanometer Measurements

# Comparisons of Standard Sphygmomanometer and Random-Zero Sphygmomanometer Blood Pressure Measurements. Visit 2, Random Sample.





# **Anthropometric Measurements**

A. Height (cm) by Age and Sex. Means and Selected Percentiles. Visit 2, Random Sample, Whites.

#### Table 48. Height (cm)

White Males - Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PEF	RCENTII	LES	
(10013)		Wicari E O.E.	Wican ± O.E.	10	25	50	75	90
0-4	20			_				
5-9	150	127.2 ± 0.7	126.2 ± 1.4 127.6 ± 0.8	116	121	126	133	140
10-14	302	153.9 ± 0.7	151.5 ± 1.5 154.5 ± 0.9	139	145	152	163	170
15-19	308	173.4 ± .05	171.8 ± 1.1 175.0 ± 1.0	164	169	174	179	183
20-24	118	178.0 ± 0.6	177.7 ± 0.9 178.8 ± 1.2	171	173	178	182	186
25-29	257	176.7 ± 0.5	$176.7 \pm 0.6$ $178.0 \pm 1.3$	169	172	177	181	185
30-34	404	177.0 ± 0.3	175.2 ± 0.7 178.3 ± 1.1	168	173	177	181	185
35-39	372	177.1 ± 0.4	174.0 ± 0.7 179.8 ± 1.1	168	173	177	182	186
40-44	388	177.3 ± 0.3	174.6 ± 0.7 178.4 ± 0.7	169	173	177	182	186
45-49	328	175.9 ± 0.4	173.8 ± 1.1 178.6 ± 0.8	168	172	176	180	185
50-54	343	175.6 ± 0.4	173.5 ± 0.8 178.8 ± 0.7	167	171	175	180	184
55-59	261	174.2 ± 0.4	172.8 ± 1.1 175.2 ± 0.8	167	170	175	178	181
60-64	131	172.4 ± 0.5	171.8 ± 1.3 173.8 ± 1.0	164	168	173	176	181
65-69	104	172.9 ± 0.5	172.6 ± 0.8 173.2 ± 0.8	166	170	173	177	179
70+	119	172.3 ± 0.6	171.9 ± 0.6 171.9 ± 0.6	165	168	172	176	181

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

#### Table 49. Height (cm)

White Females (Total) – Visit 2, Random Sample. The LRC Prevalence Study (North America).


AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.É.		PEF	RCENTII	_ES	······································
<u></u>				10	25	50	75	90
0-4	17							
5-9	127	126.5 ± 0.7	$124.5 \pm 1.3$ $127.0 \pm 0.9$	116	122	126	130	138
10-14	248	152.7 ± 0.6	152.1 ± 0.8 155.8 ± 1.9	140	145	153	160	165
15-19	298	162.8 ± 0.3	160.9 ± 0.7 163.6 ± 1.0	155	159	163	167	170
20-24	199	163.5 ± 0.4	161.0 ± 1.4 164.8 ± 0.7	156	160	164	167	171
25-29	314	164.2 ± 0.4	162.6 ± 1.0 166.7 ± 1.1	156	160	164	168	173
30-34	338	163.7 ± 0.3	163.1 ± 1.2 165.1 ± 0.9	156	160	163	168	172
35-39	304	163.5 ± 0.4	159.7 ± 1.3 165.0 ± 1.1	156	159	164	168	171
40-44	322	162.7 ± 0.5	158.2 ± 2.9 166.2 ± 1.0	155	159	164	167	170
45-49	329	162.7 ± 0.3	161.0 ± 0.8 164.6 ± 1.2	156	159	163	167	170
50-54	258	162.2 ± 0.4	159.8 ± 1.2 163.2 ± 1.0	155	158	162	167	170
55-59	251	160.4 ± 0.4	156.5 ± 1.6 162.2 ± 1.1	153	156	161	165	168
60-64	145	160.8 ± 0.5	160.3 ± 1.0 160.7 ± 0.7	154	157	161	165	168
65-69	131	158.0 ± 0.9	157.7 ± 1.4 158.0 ± 0.8	152	154	159	162	166
70+	139	157.7 ± 0.5	157.5 ± 0.8 158.0 ± 0.6	150	154	158	162	165

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Height (cm)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).







Figure 90
White Males/White Females (Total)





# Anthropometric Measurements

B. Weight (kg) by Age and Sex. Means and Selected Percentiles. Visit 2, Random Sample, Whites.

## Table 50. Weight (kg)

White Males – Visit 2, Random Sample.
The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL (Mean ± S.E.	CLINIC RANGE Mean ± S.E.	PERCENTILES					
(Tours)		WIOGIT 0.L.	Would = 0.E.	10	25	50	75	90	
0-4	20	_	<del></del>	_	_	_	_	_	
5-9	151	26.1 ± 0.4	25.4 ± 0.8 26.4 ± 0.6	20	22	25	29	33	
10-14	302	45.2 ± 0.7	43.3 ± 1.9 45.8 ± 0.9	32	36	42	53	63	
15-19	308	66.4 ± 0.7	65.6 ± 1.2 67.2 ± 1.6	52	58	64	73	84	
20-24	118	74.8 ± 1.0	72.8 ± 1.2 76.9 ± 2.2	62	66	74	81	87	
25-29	257	79.6 ± 0.9	77.7 ± 1.4 82.9 ± 3.5	65	71	77	86	95	
30-34	404	81.4 ± 0.6	77.6 ± 1.2 84.7 ± 2.0	68	73	80	88	96	
35-39	372	82.8 ± 0.7	78.2 ± 1.6 86.3 ± 3.3	68	74	81	89	99	
40-44	387	84.0 ± 0.6	81.9 ± 1.6 88.2 ± 2.2	69	75	83	91	99	
45-49	329	82.3 ± 0.7	79.1 ± 2.7 86.2 ± 2.3	68	76	81	88	98	
50-54	343	81.3 ± 0.6	77.2 ± 2.9 84.5 ± 1.9	68	74	80	88	96	
55-59	262	79.6 ± 0.7	75.7 ± 1.4 83.8 ± 2.3	65	72	79	86	94	
60-64	131	76.5 ± 1.0	75.7 ± 1.3 77.8 ± 1.9	64	69	76	82	89	
65-69	104	78.1 ± 1.1	77.7 ± 1.5 80.6 ± 2.0	67	70	76	84	93	
70+	119	75.2 ± 0.9	75.0 ± 1.0 75.0 ± 1.0	63	68	74	83	88	

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

# Table 51. Weight (kg)

White Females (Total) - Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PEF	RCENTI	LES	
				10	25	50	75	90
0-4	18		*****		-			
5-9	128	26.3 ± 0.5	24.5 ± 0.7 26.3 ± 0.6	20	23	25	28	35
10-14	248	43.4 ± 0.7	43.1 ± 0.8 46.1 ± 1.8	31	35	42	50	56
15-19	298	56.9 ± 0.6	54.3 ± 0.9 58.5 ± 1.4	46	50	56	61	69
20-24	199	60.5 ± 0.8	58.6 ± 1.4 63.5 ± 2.6	50	53	58	64	73
25-29	314	61.3 ± 0.7	58.3 ± 1.0 66.1 ± 2.5	49	54	59	65	74
30-34	338	63.0 ± 0.7	60.4 ± 1.8 68.9 ± 2.4	51	55	60	68	79
35-39	304	64.4 ± 0.8	60.3 ± 1.2 69.3 ± 2.3	51	56	61	70	83
40-44	322	65.3 ± 0.7	62.3 ± 2.0 71.9 ± 2.0	52	57	63	72	80
45-49	329	64.9 ± 0.6	60.9 ± 2.2 68.5 ± 1.8	51	57	64	72	79
50-54	259	65.6 ± 0.8	59.1 ± 1.5 72.4 ± 3.0	52	57	64	71	80
55-59	251	64.7 ± 0.8	58.7 ± 1.2 71.4 ± 1.9	51	56	62	72	81
60-64	145	65.3 ± 1.1	62.5 ± 1.6 70.0 ± 2.5	53	56	62	71	83
65-69	131	64.1 ± 1.2	62.9 ± 1.6 68.6 ± 2.0	51	56	63	69	77
70+	140	61.7 ± 0.9	61.2 ± 1.0 62.3 ± 1.5	49	54	61	68	76

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

Clinic range indicates the range among Lipid Research Clinics (the lowest LRC mean value and the highest LRC mean value) and its respective SE.

# Weight (kg)

Visit 2, Random Sample.

The LRC Program Prevalence Study (North America).

## Figure 91 **White Males**

Means and Selected Percentiles.

## Figure 92 White Females (Total) Means and Selected Percentiles.





Figure 93 White Males/White Females (Total)





# Anthropometric Measurements

C. Triceps Skinfold (mm) by Age and Sex. Means and Selected Percentiles. Visit 2, Random Sample, Whites.

# Table 52. Triceps Skinfold (mm)

White Males – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PER	CENTI	LES	
(10010)		MOUT = O.E.	Wicari E G.E.	10	25	50	75	90
0-4	20		<del></del>					_
5-9	152	12.0 ± 0.6	$6.2 \pm 0.6$ $14.8 \pm 0.8$	5	7	10	16	22
10-14	303	15.1 ± 0.5	8.4 ± 0.9 17.7 ± 0.7	6	9	14	21	27
15-19	308	15.4 ± 0.7	10.6 ± 0.8 21.8 ± 1.3	5	7	11	21	32
20-24	117	15.3 ± 0.8	11.8 ± 0.9 22.0 ± 1.1	5	9	13	21	27
25-29	257	16.3 ± 0.5	15.2 ± 1.3 20.9 ± 1.4	7	10	15	21	28
30-34	404	16.3 ± 0.5	10.5 ± 1.0 23.9 ± 1.5	7	10	15	21	29
35-39	371	16.6 ± 0.5	10.2 ± 1.1 24.8 ± 1.9	8	10	15	22	29
40-44	385	16.7 ± 0.5	11.5 ± 0.7 21.9 ± 2.3	7	10	15	21	28
45-49	329	15.8 ± 0.5	11.4 ± 0.8 20.8 ± 1.0	7	10	14	20	27
50-54	342	15.9 ± 0.4	10.9 ± 0.6 20.8 ± 0.8	7	10	15	20	26
55-59	262	14.9 ± 0.5	10.3 ± 1.0 18.9 ± 1.1	7	9	13	19	25
60-64	131	13.1 ± 0.5	10.1 ± 0.6 17.2 ± 1.3	7	9	12	15	21
65-69	103	13.1 ± 0.7	9.8 ± 0.6 19.4 ± 1.2	6	8	11	17	22
70+	118	11.7 ± 0.6	9.9 ± 0.4 9.9 ± 0.4	6	8	10	12	20

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

> Clinic range indicates the range among Lipid Research Clinics (the lowest LRC mean value and the highest mean value) and its respective SE.

# Table 53. Triceps Skinfold (mm)

White Females (Total) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PEF	RCENTII	LES	*
(Tears)		Wican ± O.E.	Wicari ± O.L.	10	25	50	75	90
0-4	18					*******	***************************************	***************************************
5-9	128	12.5 ± 0.6	$7.1 \pm 0.6$ $14.5 \pm 0.7$	5	7	12	17	21
10-14	247	16.7 ± 0.5	11.1 ± 1.1 19.1 ± 0.7	8	11	15	21	27
15-19	298	19.0 ± 0.5	12.1 ± 1.2 21.1 ± 0.9	9	13	18	24	31
20-24	198	22.1 ± 0.6	19.8 ± 1.0 25.2 ± 1.1	12	16	22	27	32
25-29	313	22.0 ± 0.5	14.0 ± 0.9 28.8 ± 1.1	11	15	21	27	35
30-34	339	21.8 ± 0.5	12.8 ± 1.0 27.7 ± 1.3	10	15	20	29	35
35-39	304	23.1 ± 0.5	15.6 ± 1.3 29.5 ± 1.3	12	16	22	29	36
40-44	320	24.4 ± 0.5	17.9 ± 1.2 31.0 ± 1.3	13	18	24	31	36
45-49	328	24.9 ± 0.5	17.0 ± 1.2 32.9 ± 1.3	14	19	24	31	37
50-54	257	24.0 ± 0.5	18.1 ± 1.0 28.1 ± 1.3	13	17	23	30	36
55-59	250	24.1 ± 0.5	20.1 ± 1.2 30.3 ± 1.3	13	19	24	30	35
60-64	145	22.5 ± 0.7	18.0 ± 1.0 29.6 ± 1.2	12	15	21	28	37
65-69	131	21.3 ± 0.7	18.0 ± 0.6 28.5 ± 1.4	13	15	20	27	32
70+	141	20.6 ± 0.7	18.5 ± 0.8 23.3 ± 1.1	11	15	20	25	31

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

> Clinic range indicates the range among Lipid Research Clinics (the lowest LRC mean value and the highest mean value) and its respective SE.

# Triceps Skinfold (mm)

Visit 2, Random Sample.

The LRC Prevalence Study (North America).



Means and Selected Percentiles.



Means and Selected Percentiles.






Figure 96
White Males/White Females (Total)

Comparison of Medians.



10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.



# **Anthropometric Measurements**

D. Quetelet Index by Age and Sex. Means and Selected Percentiles. Visit 2, Random Sample, Whites.

# Table 54. Quetelet Index

White Males - Visit 2, Random Sample.

The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PEF	CENTI	LES	
(1eais)		Mean ± 3.L.	Weart ± S.L.	10	25	50	75	90
0-4	20	Andrews .	_			_		
5-9	150	1.60 ± 0.02	1.59 ± 0.03 1.61 ± 0.02	1.43	1.50	1.57	1.67	1.81
10-14	302	1.88 ± 0.02	1.83 ± 0.04 1.89 ± 0.02	1.56	1.67	1.82	2.03	2.26
15-19	308	2.21 ± 0.03	2.16 ± 0.04 2.30 ± 0.07	1.81	1.96	2.11	2.36	2.71
20-24	118	2.36 ± 0.03	2.31 ± 0.04 2.40 ± 0.06	2.00	2.12	2.33	2.55	2.71
25-29	257	2.56 ± 0.03	2.46 ± 0.04 2.62 ± 0.10	2.12	2.29	2.47	2.73	3.00
30-34	404	2.60 ± 0.02	2.45 ± 0.03 2.68 ± 0.07	2.19	2.38	2.56	2.77	3.03
35-39	372	2.64 ± 0.02	$2.48 \pm 0.04$ $2.74 \pm 0.09$	2.20	2.40	2.62	2.84	3.04
40-44	387	2.67 ± 0.02	$2.59 \pm 0.05$ $2.78 \pm 0.06$	2.25	2.45	2.64	2.85	3.11
45-49	328	2.66 ± 0.02	2.57 ± 0.07 2.85 ± 0.06	2.28	2.46	2.63	2.84	3.10
50-54	343	2.64 ± 0.02	2.50 ± 0.07 2.76 ± 0.05	2.26	2.42	2.61	2.82	3.04
55-59	261	2.62 ± 0.02	2.51 ± 0.05 2.79 ± 0.06	2.20	2.40	2.59	2.82	3.06
60-64	131	2.57 ± 0.03	2.51 ± 0.04 2.63 ± 0.06	2.21	2.39	2.53	2.73	3.01
65-69	104	2.61 ± 0.03	2.58 ± 0.04 2.71 ± 0.07	2.24	2.37	2.58	2.78	3.02
70+	119	2.53 ± 0.03	$2.53 \pm 0.03$ $2.53 \pm 0.03$	2.16	2.33	2.51	2.74	2.97

Note: Mean not given if N < 25;

5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

Clinic range indicates the range among Lipid Research Clinics (the lowest LRC mean value and the highest LRC mean value) and its respective SE.

# **Table 55. Quetelet Index**

White Females (Total) – Visit 2, Random Sample. The LRC Prevalence Study (North America).

AGE (Years)	N	OVERALL Mean ± S.E.	CLINIC RANGE Mean ± S.E.		PEF	CENTI	LES	
(16413)		Wiedii ± O.L.	Weatt ± S.E.	10	25	50	75	90
0-4	17		withhole	<u> </u>		***************************************		_
5-9	127	1.62 ± 0.02	1.57 ± 0.02 1.62 ± 0.02	1.44	1.48	1.56	1.71	1.89
10-14	248	1.84 ± 0.02	1.85 ± 0.03 1.89 ± 0.05	1.51	1.63	1.80	1.99	2.18
15-19	298	2.15 ± 0.02	2.10 ± 0.03 2.18 ± 0.04	1.79	1.92	2.09	2.31	2.55
20-24	199	2.26 ± 0.03	2.22 ± 0.05 2.43 ± 0.10	1.91	1.99	2.19	2.40	2.66
25-29	314	2.27 ± 0.03	2.10 ± 0.03 2.52 ± 0.11	1.90	2.03	2.16	2.37	2.69
30-34	. 338	2.35 ± 0.02	2.25 ± 0.06 2.55 ± 0.10	1.96	2.06	2.22	2.49	2.98
35-39	304	2.40 ± 0.03	2.24 ± 0.04 2.55 ± 0.07	1.95	2.10	2.28	2.56	2.96
40-44	322	$2.49 \pm 0.04$	2.34 ± 0.06 2.76 ± 0.30	2.01	2.14	2.38	2.68	3.04
45-49	329	2.45 ± 0.02	2.29 ± 0.07 2.59 ± 0.06	2.02	2.15	2.37	2.67	3.00
50-54	258	2.49 ± 0.03	2.21 ± 0.05 2.76 ± 0.11	2.00	2.18	2.40	2.73	3.11
55-59	251	2.52 ± 0.03	$2.37 \pm 0.06$ $2.80 \pm 0.08$	2.00	2.19	2.42	2.75	3.16
60-64	145	2.52 ± 0.04	2.41 ± 0.06 2.72 ± 0.09	2.09	2.21	2.39	2.73	3.18
65-69	131	2.84 ± 0.33	$2.76 \pm 0.09$ $2.96 \pm 0.53$	2.06	2.23	2.45	2.76	3.10
70+	139	2.49 ± 0.03	2.45 ± 0.04 2.53 ± 0.06	1.99	2.16	2.47	2.68	2.99

Note: Mean not given if N < 25; 5th and 95th percentiles not given if N < 100; 10th and 90th percentiles not given if N < 75; 25th and 75th percentiles not given if N < 50; 50th percentile not given if N < 40.

> Clinic range indicates the range among Lipid Research Clinics (the lowest LRC mean value and the highest LRC mean value) and its respective SE.

# **Quetelet Index**

Visit 2, Random Sample.



Figure 98 White Females (Total)





Figure 99 White Males/White Females (Total)

Comparison of Medians.



Note: Mean not given if N < 25; 10th and 90th percentiles not given if N < 75; 50th percentile not given if N < 40.



Cigarette Smoking Status by Age and Sex. Visit 2, Random Sample, Whites.

**Table 56. Cigarette Smoking**Whites – Visit 2, Random Sample.
The LRC Prevalence Study (North America).

			CIGARETT	E SMOKIN	IG STATU	S		
		NEVER SMOKED	EXSMOKER	CUR < 10	RENT SMOK 10-20	ER (NUMBEF 20+	R/DAY) UNKNOWN	
MALES	AGE (Years)	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	TOTAL
	0-19	654 83.5 44.5	39 5.0 3.8	42 5.4 26.8	38 4.9 8.0	3 0.4 0.7	7 0.9 28.0	783
	20-39	400 34.8 27.2	300 26.1 29.0	54 4.7 34.4	208 18.1 43.7	179 15.6 40.0	10 0.9 40.0	1,151
	40-59	333 <sup>25.2</sup> 22.7	496 37.5 47.9	48 3.6 30.6	197 14.9 41.4	240 18.2 53.7	8 0.6 32.0	1,322
	60+	83 <sup>23.4</sup> 5.7	201 <sup>56.6</sup> 19.4	13 3.7 8.3	33 9.3 6.9	25 7.0 5.6	0 0.0	355
	Total	1,470	1,036	157	476	447	25	3,611
FEMALES	0-20	552 79.5 28.6	46 6.6 8.0	43 6.2 20.3	36 5.2 7.7	4 0.6 1.8	13 1.9 40.6	694
	20-39	554 47.5 28.7	209 17.9 36.2	78 6.7 36.8	205 17.6 44.0	111 9.5 48.5	9 0.8 28.1	1,166
	40-59	564 48.4 29.3	237 <sup>20.3</sup> 41.1	71 6.1 33.5	180 15.5 38.6	106 9.1 46.3	7 0.6 21.9	1,165
	60+	258 61.6 13.4	85 20.3 14.7	20 4.8 9.4	45 10.7 9.7	8 1.9 3.5	3 0.7 9.4	419
	Total	1,928	577	212	466	229	32	3,444

# **Cigarette Smoking Status**

Visit 2, Random Sample.

The LRC Prevalence Study (North America).







Figure 101
White Females



# Smokers by Age and Sex

Visit 2, Random Sample.

The LRC Prevalence Study (North America).

Figure 102 **White Males** 






Figure 103
White Females





Education and Occupation of Head of Household

Visit 1; Visit 2, Random Sample

Table 57. Education of Head of Household

White Males and Females—Visit 1.
The LRC Prevalence Study (North America).

							-			
					EDUCA	ATION OF HEA	D OF HOUS	EHOLD		
		>	COLLEGE	COLLEGE GRAD	SOME COLLEGE	HIGH SCHOOL GRAD	SOME HIGH SCHOOL	7th-9th GRADE	< 7th GRADE	UNKNOWN
SEX	AGE (YEARS)		N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.
MALES	0-19		929 15.1 25.1	1,180 19.1 26.5	1,029 16.7 18.6	1,814 29.4 23.0	568 9.2 24.1	460 7.5 19.4	119 1.9 19.2	75 1.2 38.5
	20-39	1	,349 15.3 36.4	1,498 16.9 33.6	2,136 24.1 38.5	2,629 <sup>29.7</sup> <sub>33.3</sub>	682 7.7 29.0	393 4.4 16.6	96 1.1 15.5	65 0.7 33.3
	40-59	1	,071 11.4 28.9	1,337 14.2 30.0	1,891 20.0 34.1	2,903 30.8 36.8	876 9.3 37.2	1,076 <sup>11.4</sup> 45.3	243 2.6 39.1	38 <sup>0.4</sup> <sub>19.5</sub>
	60+		356 <sup>13.3</sup> <sub>9.6</sub>	443 16.5 9.9	490 <sup>18.3</sup> 8.8	539 <sup>20.1</sup> 6.8	230 8.6 9.8	445 16.6 18.7	163 6.1 26.3	17 0.6 8.7
	ALL AGES	;	3,705	4,458	5,546	7,885	2,356	2,374	621	195
FEMALES	0-19		852 14.6 28.0	1,093 18.7 25.2	997 17.0 18.4	1,750 29.9 21.2	530 9.1 24.4	445 7.6 19.3	120 23.9	65 1.1 28.3
	20-39	1	,113 12.4 36.5	1,612 18.0 37.2	2,188 <sup>24.5</sup> 40.3	3,020 33.7 36.6	528 5.9 24.3	329 3.7 14.2	71 0.8 14.1	89 1.0 38.7
	40-59		776 9.1 25.5	1,139 13.4 26.3	1,656 19.5 30.5	2,879 33.8 34.9	834 9.8 38.3	1,017 <sup>11.9</sup> 44.0	158 1.9 31.5	56 0.7 24.4
	60+		307 10.4 10.1	487 16.4 11.2	586 19.8 10.8	608 <sup>20.5</sup> 7.4	285 9.6 3.1	520 17.5 22.5	153 5.2 30.5	20 0.7
	ALL AGES		3,048	4,331	5,427	8,257	2,177	2,311	502	230

Table 58. Education of Head of Household

Black Males and Females—Visit 1.
The LRC Prevalence Study (North America).

•									
				EDUCAT	TION OF HEA	D OF HOUSE	HOLD		
		> COLLEGE GRAD	COLLEGE GRAD	SOME COLLEGE	HIGH SCHOOL GRAD	SOME HIGH SCHOOL	7th-9th GRADE	< 7th GRADE	UNKNOWN
SEX	AGE (YEARS)	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.
MALES	0-19	68 4.6 46.6	79 5.3 56.8	167 <sup>11.2</sup> <sub>51.9</sub>	541 36.2 74.9	273 18.3 76.7	176 11.8 74.0	122 <sup>8.2</sup> <sub>72.2</sub>	67 4.5 97.1
	20-39	41 12.3 28.1	38 <sup>11.4</sup> <sub>27.3</sub>	102 30.5 31.7	104 31.1 14.4	33 9.9 9.3	8 2.4 3.4	6 1.8 3.6	2 0.6 2.9
	40-59	35 12.6 24.0	21 7.6 15.1	49 17.7 15.2	72 <sup>26.0</sup> 10.0	46 16.6 13.0	33 11.9 13.9	21 7.6 12.4	0 0.0
	60+	2 3.6 1.4	1 1.8 0.7	4 7.1 1.2	5 8.9 0.7	3 5.4 0.9	21 37.5 8.8	20 35.7 11.8	0 0.0
	ALL AGES	146	139	322	722	355	238	169	69
FEMALES	0-19	81 5.5 51.6	80 5.5 47.1	181 12.4 42.7	505 34.6 56.6	252 17.3 62.5	172 11.8 39.9	121 8.3 67.2	69 4.7 89.6
	20-39	42 5.9 26.8	63 8.9 37.1	191 27.0 45.1	275 38.8 30.8	84 11.9 20.8	36 5.1 12.5	10 1.4 5.6	7 1.0 9.1
	40-59	33 <sup>9.0</sup> <sub>21.0</sub>	24 6.5 14.1	49 13.4 11.6	106 <sup>28.9</sup> 11.9	59 16.1 14.6	61 16.6 21.3	34 9.3 18.7	1 0.3
	60+	1 1.8 0.6	3 5.5 1.8	3 5.5 0.7	7 12.7 0.8	8 <sup>14.6</sup> 2.0	18 32.7 6.3	15 <sup>27.3</sup> 8.3	0 0.0
	ALL AGES	157	170	424	893	403	287	180	77

**Table 59. Education of Head of Household**White Males and Females—Visit 2, Random Sample.
The LRC Prevalence Study (North America).

		V							
				EDUCA	TION OF HEA	D OF HOUSE	HOLD		
		>COLLEGE GRAD	COLLEGE GRAD	SOME COLLEGE	HIGH SCHOOL GRAD	SOME HIGH SCHOOL	7th-9th GRADE	< 7th GRADE	UNKNOWN
SEX	AGE (YEARS)	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.
MALES	0-19	130 16.6 23.8	150 19.2 23.5	127 16.2 17.9	232 <sup>21.6</sup> 22.1	59 7.5 20.7	57 7.3 19.8	17 2.2 23.9	11 1.4 47.8
	20-39	203 17.6 37.1	221 19.2 34.6	251 21.8 35.4	342 29.7 32.6	75 6.5 26.3	45 3.9 15.6	7 0.6 9.9	7 0.6 30.4
	40-59	146 11.0 26.7	212 16.0 33.2	264 <sup>20.0</sup> 37.2	398 30.1 37.9	126 <sup>9.5</sup> 44.2	145 11.0 50.4	29 <sup>2.2</sup> 40.9	2 0.2 8.7
	60+	68 19.2 12.4	55 <sup>15.5</sup> 8.6	68 <sup>19.2</sup> 9.6	77 <sup>21.7</sup> 7.3	25 7.0 8.8	41 11.6 14.2	18 5.1 25.4	3 0.9 13.0
	ALL AGES	547	638	710	1,049	285	288	71	23
FEMALES	0-19	109 15.7 24.4	125 18.0 21.3	123 17.7 17.9	227 32.7 21.0	53 7.6 19.6	48 6.9 16.4	8 1.2 13.1	1 0.1 5.9
	20-39	167 14.3 37.4	219 18.8 37.2	275 <sup>23.6</sup> 40.1	377 32.3 34.8	69 5.9 25.6	42 3.6 14.4	11 0.9 18.0	6 0.5 35.3
	40-59	129 11.1 28.9	166 14.3 28.2	225 19.3 32.8	385 33.1 35.6	102 8.8 37.8	128 <sup>11.0</sup> 43.8	24 2.1 39.3	6 0.5 35.3
	60+	42 10.0 9.4	78 18.6 13.3	63 <sup>15.0</sup> 9.2	94 <sup>22.4</sup> 8.7	46 11.0 17.0	74 17.7 25.3	18 4.3 29.5	4 1.0 23.5
	ALL AGES	447	588	686	1,083	270	292	61	17

# Table 60. Occupation of Head of Household

White Males and Females—Visit 1.

The LRC Prevalence Study (North America).

							(	DCCUP/	ATION	OF HE	AD OF	HOUSEHO	OLD						
		1	2		3		4		5	6		7		8	9		10	)	UNKNOWN
SEX	AGE (YEARS)	N % Ro	v N %	6 Row 6 Col.	N % R	ow ol. N	% Row % Col.	′ N ;	% Row % Col.	N %	6 Row 6 Col.	N % Ro	ow ol.	% Row % Col.	N %	6 Row 6 Col.	N %	Row Col.	N % Row % Col.
MALES	0-19	1,123 18.2 24.9	1,041	16.9 24.4	1,196 19 24	4 7 74	6 12.1 18.1	1,136	18.4 18.6	697	11.3 28.0	83 <sup>1.</sup> 20.	3	10 0.2 38.5	16	0.3 14.6	80	1.3 64.0	46 0.8 32.6
	20-39	1,379 15.6 30.6	1,285	14.5 30.1	1,450 16 29	4 9 1,33	2 15.1 32.4	2,339	26.4 38.3	792	9.0 31.9	103 1. 25.	2 5	3 0.0	94	1.1 85.5	18	0.2 14.4	53 <sup>0.6</sup> 37.6
	40-59	1,418 15.6 31.5	1,387	14.7 32.5	1,683 17 34	8 7 1,71	18.2 4 41.6	2,224	23.6 36.4	804	8.5 32.3	142 1. 35.	5	11 0.1 42.3	0	0.0	16	0.2 12.8	36 0.4 25.5
	60+	589 22.0 13.1	557	20.8 13.0	516 19 10	2 7 32	12.1 7.9	408	15.2 6.7	194	7.2 7.8	76 2. 18.	8 8	2 0.1 7.7	0	0.0	11	0.4 8.3	6 4.3
	ALL AGES	4,509	4,27	70	4,845	4	,116	6,1	07	2,48	87	404		26	11	0	12	5	141
FEMALES	0-19	1,037 17.7 29.0	956	16.3 24.0	1,149 19 23	6 7 72	12.5 13.6	1,100	18.8 25.3	673	11.5 26.1	95 1. 20.	6 5	3 0.1 6.4	21	0.4 9.3	60	1.0 8.4	29 0.5 23.2
	20-39	1,064 11.9 29.8	1,284	14.4 32.2	1,588 17 32	7 8 2,02	9 22.7 37.8	1,570	17.5 36.1	956	10.7 37.1	124 1. 26.	4 7	17 0.2 36.2	196	2.2 87.1	70	0.8 9.8	52 0.6 41.6
	40-59	1,002 11.8	1,168	13.7 29.3	1,597 18 32	8 9 2,15	1 25.3 40.1	1,419	16.7 32.7	788	9.3 30.5	173 2. 37.	0 3	23 0.3 48.9	7	0.1 3.1	150	1.8 21.1	37 <sup>0.4</sup> <sub>29.6</sub>
	60+	471 15.9 13.2	584	19.7 14.6	514 17. 10.	3 6 46	1 15.5 1 8.6	257	8.7 5.9	163	5.3 6.3	72 2. 15.	4 5	4 0.1 8.5	1	0.0 0.4	432	14.6 60.7	7 0.2 5.6
	ALL AGES	3,574	3,99	92	4,848	5	,370	4,3	46	2,58	80	464		47	22	5	712	2	125

# Key for Occupational Categories.

- 1 High executives, proprietors of large concerns, major professionals
- Business managers, proprietors of mediumsized businesses, lesser professionals
- 3 Administrative personnel, small independent businesses, minor professionals
- Clerical and sales workers, technical workers, owners of little businesses
- 5 Skilled manual employees
- 6 Machine operators and semi-skilled employees
- 7 Unskilled employees and small farmers
- 8 Unemployed for more than two (2) years
- 9 Student
- 10 Housewife

# Table 61. Occupation of Head of Household

Black Males and Females—Visit 1.
The LRC Prevalence Study (North America).

							1.7						
		-	···			0	CCUPATION	OF HEAD OF	HOUSEHOLD	)			
			1	2	3	4	5	6	7	8	9	10	UNKNOWN
	SEX	AGE (YEARS)	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.	N % Row % Col.					
٨	MALES	0-19	63 4.2 49.2	65 4.4 47.1	94 6.3 54.3	191 12.8 65.6	264 17.7 65.2	410 27.5 75.4	221 14.8 78.4	32 2.1 82.1	5 0.3 71.4	119 8.0 96.8	29 1.9 96.7
		20-39	35 10.5 27.3	44 13.2 31.9	47 14.1 27.2	62 18.6 21.3	63 18.9 15.6	57 17.1 10.5	20 6.0 7.1	1 0.3 2.6	2 0.6 28.6	2 0.6 1.6	1 0.3
		40-59	28 10.1 21.9	29 10.5 21.0	27 9.8 15.6	36 13.0 12.4	62 22.4 15.3	63 22.7 11.6	27 9.8 9.6	4 10.3	0 0.0	1 0.4 0.8	0 0.0
		60+	2 3.6 1.6	0 0.0	5 8.9 2.9	2 3.6 0.7	16 28.6 4.0	14 25.0 2.6	14 25.0 5.0	2 3.6 5.1	0 0.0	1 1.8 0.8	0 0.0
		ALL AGES	128	138	173	291	405	544	282	39	7	123	30
FE	MALES	0-19	61 4.2 50.8	91 6.2 51.7	88 6.0 46.8	176 12.1 40.2	252 17.3 61.3	373 25.5 58.7	206 14.1 66.0	35 <sup>2.4</sup> <sub>71.4</sub>	3 0.2 21.4	152 10.4 69.4	24 1.6 82.8
		20-39	37 5.2 30.8	54 7.6 30.7	68 9.6 36.2	201 28.4 45.9	97 13.7 23.6	160 22.6 25.2	45 6.4 14.4	8 1.1 16.3	11 1.6 78.6	23 3.3 10.5	4 0.6 13.8
		40-59	20 5.5 16.7	30 8.2 17.1	29 7.9 15.4	60 16.4 13.7	60 16.4 14.6	91 24.8	50 13.6 16.0	5 1.4 10.2	0 0.0	21 5.7 9.6	1 0.3 3.5
		60+	2 3.6 1.7	1 1.8 0.6	3 5.5 1.6	1 1.8 0.2	2 3.6 0.5	11 <sup>20.0</sup> 1.7	11 <sup>20.0</sup> 3.5	1 1.8 2.0	0 0.0	23 41.8 10.5	0 0.0
		ALL AGES	120	176	188	438	411	635	312	49	14	219	29

# Key for Occupational Categories.

- 1 High executives, proprietors of large concerns, major professionals
- 2 Business managers, proprietors of mediumsized businesses, lesser professionals
- 3 Administrative personnel, small independent businesses, minor professionals
- 4 Clerical and sales workers, technical workers, owners of little businesses
- 5 Skilled manual employees
- 6 Machine operators and semi-skilled employees
- 7 Unskilled employees and small farmers
- 8 Unemployed for more than two (2) years
- 9 Student
- 10 Housewife

# Table 62. Occupation of Head of Household

White Males and Females—Visit 2, Random Sample The LRC Prevalence Study (North America).

					OCCUPA	TION OF HEA	D OF HOUSE	HOLD				
		1	2	3	4	5	6	7	8	9	10	UNKNOWN
SEX	AGE (YEARS)	N % Row % Col.										
MALES	0-19	143 18.3 23.0	115 14.7 20.8	156 19.9 24.6	90 11.5 16.9	131 16.7 17.2	91 11.6 29.2	14 1.8 25.9	2 0.3 40.0	0 0.0	12 1.5 60.0	29 3.7 27.6
	20-39	201 17.5 32.3	169 14.7 30.6	176 15.3 27.8	162 14.1 30.3	292 25.4 38.3	88 7.7 28.2	14 1.2 25.9	0 0.0	10 0.9 90.9	3 0.3 15.0	36 3.1 34.3
	40-59	185 14.0 29.7	201 15.2 36.4	224 16.9 35.3	239 18.1 44.8	300 22.7 39.4	111 8.4 35.6	18 1.4 33.3	3 0.2 60.0	1 0.1 9.1	3 0.2 15.0	37 2.8 35.2
	60+	93 26.2 15.0	67 18.9 12.1	78 22.0 12.3	43 12.1 8.1	39 11.0 5.1	22 6.2 7.1	8 2.3 14.8	0 0.0	0 0.0	2 0.6 10.0	3 0.9 2.9
	ALL AGES	622	552	634	534	762	312	54	5	11	20	105
FEMALES	0-19	117 16.9 24.8	113 16.3 19.7	135 19.5 22.5	88 12.7 13.1	138 19.9 24.4	72 10.4 23.6	6 .0.9 14.0	0 0.0	0 0.0	6 0.9 6.4	19 2.7 20.9
	20-39	142 12.2 30.2	175 15.0 30.5	191 16.4 31.9	235 20.2 35.0	208 17.8 36.8	123 10.6 40.3	11 0.9 25.6	1 0.1 16.7	24 2.1 96.0	6 0.5 6.4	50 4.3 55.0
	40-59	147 12.6 31.2	188 16.1 32.8	211 18.1 35.2	277 23.8 41.3	186 16.0 32.9	92 7.9 30.2	19 1.6 44.2	4 0.3 66.7	1 0.1 4.0	18 1.6 19.2	22 1.9 24.2
	60+	65 15.5 13.8	97 23.2 16.9	62 14.8 10.4	71 17.0 10.6	34 8.1 6.0	18 4.3 5.9	7 1.7 16.3	1 0.2 16.7	0 0.0	64 15.3 68.1	0 0.0
	ALL AGES	471	573	599	671	566	305	43	6	25	94	91

# Key for Occupational Categories.

- 1 High executives, proprietors of large concerns, major professionals
- 2 Business managers, proprietors of mediumsized businesses, lesser professionals
- 3 Administrative personnel, small independent businesses, minor professionals
- 4 Clerical and sales workers, technical workers, owners of little businesses
- 5 Skilled manual employees
- 6 Machine operators and semi-skilled employees
- 7 Unskilled employees and small farmers
- 8 Unemployed for more than two (2) years
- 9 Student
- 10 Housewife

# References

- 1. The LRC Program Epidemiology Committee. Plasma Lipid Distributions in Selected North American Populations: The Lipid Research Clinics Prevalence Study. Circulation 60:427, 1979.
- 2. US-USSR Steering Committee for Problem Area 1. The Pathogenesis of Atherosclerosis. Collaborative US-USSR Study on the Prevalence of Dyslipoproteinemias and Ischemic Heart Disease in American and Soviet Populations. Am J Cardiol 40:260, 1977.
- 3. Central Patient Registry and Coordinating Center for the Lipid Research Clinics. Reference Manual for the Lipid Research Clinics Program Prevalence Study. Volumes 1 and 2. Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, February 1974.
- 4. Manual of Laboratory Operations, Lipid Research Clinics Program. Volume 1: Lipid and Lipoprotein Analysis. National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland. DHEW Publication Number (NIH) 75-628. May 1974.

# **Key Personnel Involved in Data Collection for Visit 1 and Visit 2 of the LRC Prevalence Study**

# **Lipid Research Clinics**

# **Baylor College of Medicine**

#### LRC Directors:

Antonio M. Gotto, Jr., M.D., O. David Taunton, M.D., William Insull, Jr., M.D.

#### Prevalence Directors:

Reuel A. Stallones, M.D., M.P.H., Bobbe Christensen, Ph.D.

## **Key Personnel:**

Bettie Anderson, Sally Barganier, Deborah Bonnette, Marshella Bradford, Margaret Chappell, Mary Ann Gregurich, Robert Guardiola, Joanne Jackson, Jean King, Maria Lopez, Elizabeth Manis, Carolyn McGee, John Napier, Marcia Perkins, Inga Reis, Lynne Scott, Denise Tobias, Shan-Pou Tsai, Betty Tung, Elizabeth Willatt, Sandra Zeto.

## University of California, San Diego

## LRC Director:

W. Virgil Brown, M.D.

#### **Prevalence Director:**

Elizabeth Barrett-Connor, M.D.

## **Key Personnel:**

Nancy Aker, Wendy Carman, Jean Hemingway, Donna Hilt, Roberta Maxwell, Judy McConnell, Beverly Morris, Richard Postlethwait, Sharon Rosenlof, Nancy Rotchstein, Jackie Sooter, Eileen Taylor, Beverly Tucin, Robert Wallace.

## **University of Cincinnati**

#### LRC Director:

Charles J. Glueck, M.D.

#### Associate LRC Director:

Ido deGroot, M.P.H.

## **Prevalence Directors:**

John A. Morrison, Ph.D., Kathe Kelly, B.S.

#### **Key Personnel:**

Suzy Bowers, Phil Khoury, Margot Mellies, Paula Steiner, Peggy Stone, Sandra Tillett.

## **University of Iowa**

#### LRC Directors:

Francois Abboud, M.D., William Connor, M.D.

## Prevalence Director:

Robert Wallace, M.D.

## **Key Personnel:**

Kathy Barney, Jorgie Bendull, Joan Bickel, Linda Chandler, Rhonda Flemming, Winnie Fields, Frances Giron, Robert Greiner, Jane Hronik, Linda Izumi, Mary Nell Jackson, Linda Johnson, Mary Ann Kamp, Phillip Karp, Paul King, Sandy McCoy, Nancy Merideth, Audrey Peham, Wayne Proeger, Karen Smith, Linda Snetselaar, Barbara Tillmans, Michael Tribby, Laura Vailas, Theresa Viner, Don Weibe, Evelyn Williams.

## Johns Hopkins University

#### LRC Director:

Peter O. Kwiterovich, Jr., M.D.

#### Prevalence Directors:

Peter O. Kwiterovich, Jr., M.D., Gary Chase, Ph.D.

# Key Personnel:

Linda Allnutt, Kit Alvaro, Paul Bachorik, Beverly Banks, Sadie Brooks, Carol Brown, Ronald Covington, Elaine DiMario, Cathy Dobson, Betty Foley, Barbara Green, Barbara Griffin, Jeff Jenkins, Sandy Jones, Helen Kindt, Shirley Lin, Geraldine Logan, Joanne Lorie, Jean Marini, Sharon McFarland, Dorothy Miller, Andrew Oppel, Cecil Parker, Renita Patton, Ann Pendleton, Meg Prior, Kathy Salz, Marianne Schierloh, Hazel Smith, Henrietta Toney, Vickie Turner, Herbert Ward, Connie Webster, Susan Willoughby, Diane Zeitler.

# **University of Minnesota**

#### LRC Director:

Ivan D. Frantz, Jr., M.D.

#### **Prevalence Director:**

Henry L. Taylor, Ph.D.

#### Co-Directors:

David R. Jacobs, Ph.D., Donald Hunninghake, M.D.

## **Key Personnel:**

Ardys Anderson, Catherine Bell, Richard Berg, Thomas Birch, Ruth Boyd, Elizabeth Brewer, Christine Brueggemann, Lynn Callies, Jean Canner, Kathryn Caspers, Kenneth Chang, Elizabeth Chisholm, Emily Dawson, Mary Dempsey, Susan DeZeller, Alan Ducommun, Barbara Dusckas, Marita Ener, Maurita French, Barbara Frokjer, William Fuller, Curt Furberg, June Hamerski, Peter Hannan, Diane Harrington, Eileen Harrington, Stephanie Hencir, Rosemarie Hilk, Veronica Hill, William Horns, Sven-Olaf Isaacson, Lars Janzon, Shirley Jones, Joan Knudsen, Janet Kortuem, Eunice Kreiger, Kanta Kuba, Kay Kurtz, Monica LaDouceur, Lynn Lau, Arthur Leon, Marguerite Lieske, Dorothy Meinke, Olga Nicole, Mary Ann O'Brien, Helen Palmer, Mari Palta, Lynette Permaul, Florine Peterson, Jeffrey Probstfield, Patricia Redick, David Regel, Beth Rollie, Valentine Ruf, Edward Rykken, Sandra Schifsky, Bettey Schloner, Carol Schmid, Bondalyn Schmitz, Norris Schulz, Margaret Schutz, Gretchen Sjoholm, Lois Stark, Gwen Stevens, Thomas Sutton, Marilyn Swenson, William Swing, Erica Trapp, Eula Vickers, John Vilandre, Karen Virnig, Arlene White, Allan Womelsdorf, Gary Zimmerman.

#### Oklahoma Medical Research Foundation

#### LRC Director:

Reagan H. Bradford, M.D.

#### Prevalence Director:

Paul Anderson, Jr., Ph.D.

## **Key Personnel:**

Mary Brockway, Donnalee Cowden, Judith Hill, Jerry Hillerman, Patricia Hyder, Arden Mackenthun, Ken Smith, Bonnie Wilds, Paula Willis.

# **Stanford University**

#### LRC Director:

John W. Farguhar, M.D.

#### **Prevalence Directors:**

William L. Haskell, Ph.D.

## **Key Personnel:**

Silvia Aguado, Judy Bailey, Betty Breedlove, Fran Carl, Cassie Crouch, Ruth Dennis, Carmelita Dizon, Cay Fotopolos, John Green, Husein Halilovic, Doug Jocobs, Sherry Jensen, Joy Jinkerson, Lillian Karlsson, Benjamin Liu, Jorge Motta, Virginia Peterson, Anne Schlagenhaft, Michael Stern, Edelen Stevens, Phyllis Ullman, Mary Upton, Peter Wood.

# University of Toronto and McMaster University

#### LRC Director:

Alick Little, M.D.

#### Prevalence Director:

David Hewitt, M.A.

## **Associate Prevalence Directors:**

J. Bird, M.D., M. Mishkel, M.D., G. Steiner, M.D.

#### **Key Personnel:**

R. Aust, L. Barrett, M. Beaton, P. Bradley, L. Brown, M. Buck, K. Camelon, R. Chisolm, K. Christie, C. Conner, J. Cook, M. Cousins, H. A. Dillon, W. Ferris, P. Forbath, Gaetan Godin, B. Guy, Judy Halloran, N. Heidenreich, Hilda Hennig, I. Hronsky, L. Hull, J. Johnson, J. Keiser, V. Keremetlian, Mary Leech, M. Marsella, Val McGuire, Kathleen O'Brien, Jane O'Leary, A. O'Toole, D. Pirhonen, D. Ridout, T. Robinson, Diane Rosen, S. Santarossa, L. Schwartz, B. Sealey, B. Seeley, G. Sibenik, M. Sims, D. Stewart, E. Stewart, N. Swami, M. Thompson, Sylvia Thompson, E. Timar, A. Tyrrell, Lucia Vialva, A. Webber, P. Whitfield, E. D. Wigle, J. K. Wilson, D. Wotherspoon, Doreen Wraight.

#### University of Washington (Seattle)

#### LRC Directors:

Edwin Bierman, M.D., William R. Hazzard, M.D.

#### **Prevalence Directors:**

J. Joanne Hoover, M.D., M.P.H., Patricia Wahl, Ph.D.

# **Key Personnel**

John Albers, John Bagdade, Janice Bate, Robert Bergelin, Edward Bierman, Judith Bowlin, Beth Burrows, Ellen Champbell, Kathleen Corr, David Dora, Grace Dunlap, Donald Franklin, Willard Johnson, Daryl Jones, Warner Kebsch, Betty King, Robert Knopp, Gail McChesney, Marjorie Pearl, Roger Peterson, Margaret Poole, Allan Pribble, Carolyn Walden, Russell Warnick, Chien Yu.

# **Central Support Agencies**

# Central Patient Registry and Coordinating Center CPR Director:

O. Dale Williams, Ph.D.

**Past Director:** 

James Grizzle, Ph.D.

**Prevalence Director:** 

Richard Mowery, M.S., M.S.P.H.

**Key Personnel:** 

David Boyd, Marriotte Churchill, Gerardo Heiss.

# Central Electrocardiographic Laboratory (CEL)

Director:

L. Thomas Sheffield, M.D.

Co-Director:

David Roitman, M.D.

Co-Director:

Santosh Kansal, M.D.

# **Key Personnel:**

Bill Alexiou, Lisa Copeland, Shirley Decker, Linda DeVault, Lisa Devinish, Myrnie Driskill, Claudia Flores, Evette Green, Audrey Howard, Donita Johnson, Melinda Johnson, Bobby Jordan, Ron Kittinger, Mary Kay Richards, Ruth Robinson, Jo Ann Romph, Paula Stanton, Janell Sullens, Carol Troxell, Monika Whitcomb.

# Lipid Standardization Laboratory, Center for Disease Control

Director:

Gerald R. Cooper, M.D.

**Key Personnel:** 

James Gill, Adrian Hainline, Myron Kuchmak, Carole Winn.

# **Nutrition Coding Center**

Director:

P. Victor Grambsch

**Deputy Director:** 

Naseem Kassim

**Key Personnel:** 

Margaret Estes, Marilyn Twogood, Joyce Wenz.

# **Program Office**

Lipid Metabolism Branch, Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health

#### Director:

Basil M. Rifkind, M.D.

#### Past Director:

Robert I. Levy, M.D.

# **Prevalence Study Coordinators:**

Marian Fisher, Ph.D.; Gary Fisher, M.D. (past); Barry Greenberg, M.D. (past); Robin Harris, M.P.H. (past)

## Key Personnel:

Nancy Ernst, Robert Havlik, Virginia Keating, Kenneth Lippel, Barbara Roberts.

# Committees

# **Epidemiology Executive Committee**

# Herman A. Tyroler, M.D.—Chairman

Mary Brockway, Ph.D., Manning Feinleib, M.D., Marian Fisher, Ph.D., Gerardo Heiss, M.D., John LaRosa, M.D., Jack Medalie, M.D., Basil M. Rifkind, M.D., Henry Taylor, Ph.D., Robert Wallace, M.D., O. Dale Williams, Ph.D.

## Ad Hoc Members

J. Alick Little, M.D., Carl Rubenstein, M.D., L. Thomas Sheffield, M.D.

#### **Past Members**

Robin Harris, M.P.H., Joanne Hoover, M.D., John O'Sullivan, M.D., William J. Schull, Ph.D.

## **Epidemiology Committee**

## Chairman:

Herman A. Tyroler, M.D.

#### Members:

Paul Anderson, Ph.D., Elizabeth Barrett-Connor, M.D., Mary Brockway, Ph.D., Gary Chase, Ph.D., Bobbe Christensen, Ph.D., Michael Criqui, M.D., Michael Davies, M.D., Alexander Deev, Ph.D., Ido de Groot, M.P.H., Manning Feinleib, M.D., Marian Fisher, Ph.D., Igor Glasunov, M.D., Gaetan Godin, M.S., S. T. Halfon, M.D., Robin Harris, M.P.H., William Haskell, Ph.D., Gerardo Heiss, M.D., Ph.D., David Hewitt, M.A., Judith Hill, M.S., Joanne Hoover, M.D., Ph.D., David Jacobs, Ph.D., Kathe Kelly, M.S., Alick Little, M.D., Arden Mackenthun, Ph.D., Irma Mebane, M.S., Jack Medalie, M.D., Richard Mowery, M.S.P.H., John Morrison, Ph.D., John B. O'Sullivan, M.D., Basil M. Rifkind, M.D., Carl Rubenstein, M.D., William J. Schull, Ph.D., Dimitri Shestov, M.D., Henry Taylor, Ph.D., Pearl Van Natta, Ph.D., Robert Wallace, M.D., O. Dale Williams, Ph.D., Andrei Zadoja, M.D.

# Lipid Metabolism Advisory Committee

	4070 4070
Margaret J. Albrink, M.D.	1972-1976
Daniel L. Azarnoff, M.D.	1971-1973
Sidney Blumenthal, M.D.	1973-1975
Merme Bonnell	1973-1974
Robert F. Bradley, M.D.	1971-1974
M. Elizabeth Campbell	1974-1975
Bernard D. Challenor, M.D.	1975-1978
William E. Connor, M.D.	1971-1972
	1971-1972)
Margaret O. Dayhoff, Ph.D.	1972-1975
Allen Drash, M.D.	1975-1979
Howard A. Eder, M.D.	1976-1980
	1978-1980)
Harold J. Fallon, M.D.	1974-1977
(Chairman,	1976-1977)
Agnes G. Fry	1971-1973
DeWitt S. Goodman, M.D.	1978-1982
Frederick T. Hatch, Ph.D., M.D.	1972-1976
Norge W. Jerome, Ph.D.	1978-1982
Genell L. Knatterud, Ph.D.	1975-1979
Bruce A. Kottke, Ph.D., M.D.	1976-1980
Robert J. Levine, M.D.	1977-1981
Frank T. Lindgren, Ph.D.	1971-1981
	1971-1972
Bernard Lown, M.D.	1975-1979
Dean T. Mason, M.D.	1971-1975
Erwin H. Mosbach, Ph.D.	1974-1978
	1977-1978)
Arno G. Motulsky, M.D.	1976-1980
Alexander V. Nichols, Ph.D.	1972-1976
(Chairman,	1972-1976)
Robert P. Noble, M.D.	1971-1972
Adrian M. Ostfeld, M.D.	1971-1972
John B. O'Sullivan, M.D.	1975-1979
Barbara A. Rennick, M.D.	1973-1974
William J. Schull, Ph.D.	1972-1976
Herman A. Tyroler, M.D.	1973-1975
Bernice K. Watt, Ph.D.	1976-1980
William H. Weidman, M.D.	1970-1980
Donald B. Zilversmit, Ph.D.	1971-1974

# **Executive Secretary**

Robert I. Levy, M.D.	1971-1974
Basil M. Rifkind, M.D.	1974-present

This Data Book was prepared by Gerardo Heiss, M.D., Ph.D., Irma Mebane, M.S., and Israel Tamir, M.D., with editorial assistance from Janet Bungay.

DATE DUE			
GAYLORD			PRINTED IN U.S.A.

NIH LIBRARY 4 0134 5685



http://nihlibrary.nih.gov

10 Center Drive Bethesda, MD 20892-1150 301-496-1080 vIINATION PROHIBITED: Under provisions of applicable public ted by Congress since 1964, no person in the United States shall, pund of race, color, national origin, sex, or handicap, be excluded icipation in, be denied the benefits of, or be subjected to discrimider any program or activity receiving Federal financial assistance. In, Executive Order 11141 prohibits discrimination on the basis of antractors and subcontractors in the performance of Federal conterefore, the National Heart, Lung, and Blood Institute must be in compliance with these laws and executive order.



